Index

Note: Page entries referring to figures are in italics; tables are noted with t.

ACE inhibitors, for chronic daily headaches, 263–264
Acetaminophen, 68, 70
  adverse effects of, 50
  cancer pain management and, 219
  chronic musculoskeletal pain and, 50–51
for chronic orofacial pain, 33–34
dosage of, 50
efficacy for chronic pain, 50
episodic headaches and, 51
indications for, 47, 50
Medline search: classification, orofacial pain, facial
  pain, pain, 31t
oral formulations and dosing protocol for, 48t
osteoarthritis and, 50
preventative analgesia and, 61–62
Acetretin, for OLP treatment, 202
Acetylsalicylic acid, 86
Acquired immunodeficiency syndrome, 18
  neuropathy induced by, 95
  key features of, summary, 96t
ACR. See American College of Rheumatology
Acupressure, 164
  for fibromyalgia or myalgia, 280
Acupuncture
  cancer pain and, 226
  for orofacial pain and spasm, 164–165
Acute abortive treatment
  for cluster headache, 257
  for episodic migraines, 256
Acute trigeminal neuritis
  confirmatory or exclusionary diagnostic methods, 9t
distinguishing clinical features, 5t
Acyclovir, for chronic facial pain, 41
Adderall, extrapyramidal reactions and, 339
Addiction Research Inventory, 67–68
ADHD. See Attention deficit hyperactivity disorder
Adipex, extrapyramidal reactions and, 339
Adjuvant analgesics
  cancer pain management and, 219–220, 221t, 226
defined and administration of, 76
Adverse events
defined and calculated for four medication groups, 38
  nocebo-responsive patient and, 85
Advil, for orofacial pain, 157
AEDs. See Antiepileptic drugs
Aerobic exercise, for fibromyalgia, 280, 281
AES. See Adverse events
AES 14, 191
Age/aging
  articular cartilage thinning and, 311
  burning mouth syndrome and, 20
  headaches and, 16
  oral motor disorders and, 22
  osteoarthritis and, 312
  osteoarthritis of TMJ and, 14
  postherpetic neuralgia and, 19
  psychopharmacologic agents and, 139
  pulp circulation and, 303
tardive dyskinesia and, 23
temporal arteritis and, 15
TMJ disease and, 311–312
  trigeminal neuralgia and, 96
AIDS. See Acquired immunodeficiency syndrome
Akathisia reactions, extrapyramidal syndrome reaction
  and, 336
Akinesia, Parkinsonism and, 336

© 2012 John Wiley & Sons, Inc. Published 2012 by John Wiley & Sons, Inc.
ALA. See Alpha-lipoic acid
Allergic contact stomatitis
causation, 194
clinical presentation, 194
etiology, 193
Allergic reactions, oral ulcerative disease and, clinical features, 192
Allergy tests, burning mouth syndrome and, 236
Allergic contact stomatitis
causation, 194
clinical presentation, 194
etiology, 193
Allergic reactions, oral ulcerative disease and, clinical features, 192
Allogeneic hematopoietic stem-cell or bone marrow transplantation, graft-versus-host disease and, 202
Alpha-lipoic acid, for burning mouth syndrome, 240, 242
Alpha-2-adrenergic agonists, for cancer pain management, 221
Alprazolam, 116
for chronic orofacial pain, 40–41
efficacy for musculoskeletal pain associated spasm, 123
Medline search: classification, orofacial pain, facial pain, pain, 31
Amantadine
for cancer pain management, 221
for recurrent neuroleptic-induced dystonic reactions, 336
for suppressing extrapyramidal reactions, 334
Ameloblastomas, neurosensory deficits and, 218
Amerge, for episodic migraines, 256
American Academy of Neurology, 96
American Academy of Sleep Medicine Classification of Sleep Disorders, 330
American College of Rheumatology, 38, 273, 315, 322
criteria for fibromyalgia, 11
recommendations for chronic orofacial pain, 62
American Dental Association, guidelines for prescribing antibiotics, 148
American Pain Society, 73
American Society for Microbiology (ADM) Task Force, 148
American Society of Interventional Pain Physicians, 74
Amifostine, reducing severity of oral mucositis with, 190–191
Aminoglycoside antibiotics, antinociceptive action of, 146
Amiodarone
neuritis/neuropathies and, 98
medication-induced, 18
Amisulpride, for burning mouth syndrome, 240, 242
Amitriptyline, 77
for chronic daily headache or chronic migraine, 260
for chronic orofacial pain, 38
description, mechanism of action, and primary indications, 132
efficacy for fibromyalgia, 133, 283
efficacy for neuropathic pain disorders, 133
Medline search: classification, orofacial pain, facial pain, pain, 31
metabolism, side effects, and adverse drug reactions, 132–133
for pain control: FDA approval, off-label use, dose, 130
for painful diabetic neuropathy, 108
starting dose, 132
Amoxicillin, dental pulpal infections and, 145
Amphetamines, extrapyramidal reactions and, 337
Analgesia, preventative, 61–62
Analgesics, 85
choosing, 76–77
for chronic daily headaches, 17
for chronic orofacial pain, 32–34
systemic, for pain control in oral mucositis, 188
topical, 88
withdrawal from, 260
Anatomic localization, age predilection and, 6
Anesthetic-assisted joint mobilization, for DDNR, 349–350
Anesthetic challenge test, in neuropathy diagnosis, 302–303
Anesthetic injection into muscle tissue, inadvertent, secondary myalgia and, 10
Anesthetic management, cancer pain and, 223–224
Anesthetics, topical, 87–88
Anesthetic test
armamentarium, 157
diagram for, 156
visual analog scale for, 155
Angiotensin receptor blockers, for chronic daily headaches, 263–264
Ankylosing spondylitis, 320
Antibacterial agents as analgesics in chronic pain, 145–149
downside effects of frequent use of antibiotics for persistent pain, 148
indirect effect of antibiotics on tooth pain, 145
introduction, 145
known antinociceptive action of various antibiotics, 145–147
aminoglycoside antibiotics, 146
beta-lactam antibiotics, 145–146
chemically modified tetracyclines, 147
nucleoside antibiotics, 147
tetracycline-class antibiotics, 146–147
placebo effect of antibiotics, 147–148
recommendations for, 148–149
Antibacterial drugs, for chronic orofacial pain, 41–42
Antibacterial mouthrinses, oral ulcerations and use of, 198
Antibiotic resistance, frequent antibiotic use and, 148
Antibiotics
ADA guidelines for prescription of, 148
downside effects with frequent use for persistent pain, 148, 149
expectation fulfillment and, 147–148
indirect effect of, on tooth pain due to reduction of swelling and inflammation, 145
known antinociceptive action of, 145–147
aminoglycoside antibiotics, 146
chemically modified tetracyclines, 147
nucleoside antibiotics, 147
tetracycline-class antibiotics, 146–147
Medline search: classification, orofacial pain, facial pain, pain, 31
placebo effect of, 147–148
recommendations on use for pain suppression, 148–149
Anticholinergic therapy, for dystonia, 334
Anticonvulsant drugs, 76, 86, 100–108
carbamazepine, 100–102
for cancer pain management, 220, 221
for chronic orofacial pain, 35–36
FDA advisory on risk of suicidal behavior or ideation, 100
gabapentin, 104–105
lamotrigine, 103–104
levetiracetam, 104
lidocaine, 107–108
for musculoskeletal pain, 286, 289
newer, therapeutic drug monitoring for, 108
opioids co-administered with, 77
oxcarbazepine, 102–103
phenytoin, 103
pregabalin, 105–106
as preventatives for chronic daily headache, 261
recommendations
for chronic neurogenic pain, 108–109
for neurogenic and neuropathic pain, 108
topiramate, 107
valproic acid, 106–107
zonisamide, 104
Antidepressants, 129
anticholinergic side effects and dosing of, 30
for burning mouth syndrome, 240, 243, 244
opioids co-administered with, 77
pain suppression and, 131–137
norepinephrine reuptake inhibitors, 135–136
overview, 131
selective serotonin reuptake inhibitors, 134–135
serotonin and norepinephrine reuptake inhibitors, 131, 134
serotonin receptor modulators, 136
serotonin-related adverse drug events, 137
tricyclic antidepressants, 132–133
periodic leg movements and, 336
Antiemetics, for episodic migraines, 256
Antiepileptic drugs
for chronic orofacial pain, 35–36
for cluster headaches, 265
therapeutic drug monitoring for, 108
Antihypertensives, as preventatives for chronic daily headache, 262–263
Anti-infl ammatory therapy, for DDNR, 349
Antimalarial drugs, 320
Antipsychotics, 129
for burning mouth syndrome, 240, 243
fibromyalgia and, 140
oral tardive dyskinesia and, 23
pain and, 137
description, mechanism of action, and primary indications, 137
FDA approval, off-label use, dose, 130
fibromyalgia, 137
metabolism, side effects, and adverse drug reactions, 137
neuropathic pain disorders, 137
starting dose, 137
Antispasmodics, for chronic orofacial pain, 39–40
Antispasticity drugs, 119–124
baclofen, 120–121
dantrolene, 122–123
diazepam, 123–124
measurement of treatment efficacy, 120
overview, 119–120
recommendations for, 124–125
skeletal muscle relaxants vs., 116
tiagabine, 121
tizanidine, 121–122
Antivirals
for chronic facial pain, 41
Medline search: classification, orofacial pain, facial pain, pain, 31
Anxiety
burning mouth syndrome and, 235
chronic pain and, 38, 140
Anxiolytics, 30, 129
pain and
description, mechanism of action, and primary indications, 138
metabolism, side effects, and adverse drug reactions, 138
myofascial pain, 138
neuropathic pain disorders, 138
starting dose, 138
for pain control: FDA approval, off-label use, dose, 131
AO. See Atypical odontalgia
Aphthous stomatitis, recurrent, 192
Aphthous ulcers, 22
ARI. See Addiction Research Inventory
Arthralgia, 13
  NSAIDs for, 157
  TMJ and, 311
Arthritis. See also Temporomandibular joint arthritis
  internal derangement and, 345, 345
  of local temporomandibular joint, 13–14
  NSAIDs for, 157
  orofacial pain and, 6
Arthrocentesis
  for DDNR, 350
  for TMJ arthritis, 318–319
Arthroscopic treatment, of DDNR, 350–351
Arthrosis, TMJ and, 311
AS. See Ankylosing spondylitis
ASA. See Acetylsalicyclic acid
Ashworth scale, measurement of antispasticity treatment
efficacy, 120
Asian populations, carbamazepine and adverse reactions
in, 101
Aspercreme, 88
Aspirin, 70
  adverse effects of, 53
  cardioprotective effect of, 61
  for chronic orofacial pain, 33–34
  dosage for, 53
  efficacy for chronic pain, 53
  indications, 52–53
  Medline search: classification, orofacial pain, facial
  pain, pain, 31
  oral formulations and dosing protocol for, 48
ATP energy crisis, peripheral muscle nociceptor
  sensitization and, 276
Atrophic tongue, 235
Attention deficit hyperactivity disorder, 337
Atypical facial pain, psychiatric co-morbid disease with, 298
Atypical odontalgia, 18, 87, 154, 178
  ketamine and, 41
  opioids used for, 74
  patient characteristics, 296–297
  persistent, final recommendations for, 306
Aura, migraine and, 16
Auriculotemporal (AT) nerve, 321
  description and sensitization of, 152
  neuropathic changes in, 158
  sensitization of, chronic trigeminal nerve pain and, 297
Auriculotemporal nerve block (TMJ joint injection)
  for orofacial pain, 152–153
  right-sided, with 2% lidocaine without epinephrine,
  153
  setup for, 152
Autoimmune arthritis, facial pain and, 14–16
Autonomic cephalalgias
  clinical criteria, 16
  etiology, 16
Avoidance therapy
  for DDWR, 347–348
  for masticatory myogenic pain, 278
Ayurveda, cancer pain and, 226
Azathioprine, 320
  for autoimmune oral mucosal reaction
    adverse reactions, 202
    indications and dosing, 202
Azithromycin, for chronic orofacial pain, 41–42
Baclofen, 79, 116
  for chronic orofacial pain, 40
  D- and X-level interactions with, 125
  description, mechanism of action, and primary
  indications for, 108, 120
  efficacy for musculoskeletal pain associated spasm,
  120–121
  for flexor spasms, 121
  Medline search: classification, orofacial pain, facial
  pain, pain, 31
  metabolism, side effects, and adverse drug reactions,
  120
  neuropathic pain disorders and, 108
  side effects and adverse drug reactions, 108
  starting dose, 108, 120
  trigeminal neuralgia and, 108
Bacterial-induced polyneuritis, causes of, 18
Bacterial infections, oral ulcerative disease and, clinical
  features, 192
Bald tongue, 235
Barbiturates, for chronic daily headaches, 17
Bath therapy, cautionary, for obese or hypertensive
  patients, 279
Behavioral treatment
  for chronic muscle pain, 281–282
  for cluster headaches, 265
Behçet’s disease
  causation, 196
  clinical features, 192
  clinical presentation, 196
  etiology, 193
Behçet’s ulcer, 22
Bell’s palsy, 41, 326, 336
Benign mucous membrane pemphigoid, 195
  causation, 195
  clinical criteria, 21
  clinical presentation, 195
  confirmatory or exclusionary diagnostic methods, 9
definitive diagnosis of, 196
distinguishing clinical features, 5t
etiology of, 8t, 21
methylprednisolone and, 60
Benzocaine, 85
for chronic orofacial pain, 35
Medline search: classification, orofacial pain, facial
pain, pain, 31t
Benzodiazepines, 30, 39, 116
for chronic daily headaches, 17
for chronic orofacial pain, 40–41
Benztropine, for dystonia, 334
Benzydamine hydrochloride, reducing severity of oral
mucositis with, 190
Beta-adrenergic receptor blockers, migraine prevention
and, 37
Beta-blockers, for chronic daily headaches, 263
Beta-lactam antibiotics, antinociceptive action of, 145–146
Betamethasone, glucocorticoid potency and duration of
action, 199t
Biofeedback, cancer pain and, 226
Biomechanical loading, abnormal, internal derangement
and, 345t, 346
Biperiden, for dystonia, 334
Bisphosphonates, 320
Blepharospasm, 23, 333, 336
Blindness, temporal arteritis and, 15
Blink reflex testing, burning mouth syndrome and, 233–234
Blistering disorders
benign mucous membrane pemphigoid, 21
lichen planus, 21
mucositis, 21–22
orofacial pain due to, 20
other chronic ulcerative conditions, 22
pemphigus vulgaris, 20–21
Blood-disease related oral ulcers
clinical features, 192t
etiology, 193t
BMMP. See Benign mucous membrane pemphigoid
BMS. See Burning mouth syndrome
Bone pain, metastatic jaw bone lesions and, 22
BoNT. See Botulinum neurotoxin
Bortezomib therapy, chemotherapy-induced peripheral
neuropathy and, 213
Botox, 170
Botulinum neurotoxin, serologically distinct subtypes, 169
Botulinum toxin
for chronic daily headache or chronic migraine, 260t
for chronic daily headaches, 264–265
dystonia managed with, 334
as a medicine, 169–171
adverse events and side effects, 170–171
injection preparation, dosing, and effect duration, 170
mechanism of action, 170
“off-label” use, 170
“on-label” use, 169–170
Medline search: classification, orofacial pain, facial
pain, pain, 31t
in orofacial pain disorders, 169–178
for oromandibular motor disorders and facial spasms,
171–172
bruxism, 171
hemifacial spasm, 172
hemimasticatory spasm, 172
hyperactivity of the tongue, 172
masseteric and/or temporalis muscle hypertrophy, 171
oromandibular dystonia, 172
secondary masticatory muscle spasm, 171
pain and, 172–176
chronic migraine, 175
chronic tension-type headache, 175–176
experimental pain in humans, 172–173
focal chronic orodental neuropathic pain, 176
myofascial trigger points, 173–174
temporomandibular pain and dysfunction, 174–175
for spasticity control in cancer patients, 215
for trigeminal autonomic cephalalgia, 177
for trigeminal neuralgia, 176–177
Botulinum toxin type A
for bruxism, 332–333
cancer pain studies and, 222–223
for chronic orofacial pain, 40
final recommendations on, 177
trigger-point injections for myofascial pain and-166, 165
Botulinum toxin type B, 169
Bouchard’s nodes, 319
Brain tumor headache, 249
Bruxism, 116, 326, 327t, 330–333, 345, 345t
botulinum toxin and, 171
characteristics of, 330
clinical criteria, 24
clonazepam and, 124
confirmatory or exclusionary diagnostic methods, 9t
defined, 23
distinguishing clinical features of, 6t
etiology of, 8t
harmfulness of, 332
osteoarthritis and, 312
osteoarthritis of TMJ and, 14
pathophysiology of, 330–331
prevalence of, 330
sleep status, actual frequency, duration, and amplitude
of, 331
SSRI-induced, 337
Bruxism (cont’d)
treatment methods for, 332–333
  botulinum toxin type A injections, 332–333
  comparison studies on, 333
  contingent feedback devices, 332
  medications for, 332
  occlusal appliances for, 332
unknown etiology of, 24
Buccal nerver territory (BUC), 321
Bullous diseases, orofacial pain due to, 20
Bullous pemphigoid, orofacial pain due to, 20
Bupivacaine, trigger-point injections for orofacial pain and
  spasm and, 165
Bupropion, for pain control: FDA approval, off-label use,
  dose, 130t
Burning mouth
  confirmatory or exclusionary diagnostic methods, 9t
  distinguishing clinical features, 5t
  symptoms of, 19–20
  clinical criteria, 19–20
  etiology of, 8t, 20
Burning mouth syndrome, 20, 30, 178, 232–243, 305
  bald or atrophic tongue, 235
  common co-morbid systemic diseases, 235
  current etiologic theories, 237–239
  CNS pain pathway and dopamine receptor alteration
  theory, 239
  dysfunction of chorda tympani nerve theory, 238
  lichen planus and, 239
  small afferent fiber atrophy theory, 238
  upregulated TRPV1 receptor theory, 238–239
  diagnosis of, 232–233
  character, 232
  clinical presentation, 232
  location, 232
  onset and pattern, 232
  tests, 232–233, 236t
geographic tongue, 235
management strategies for, 239–240, 243
  cognitive behavioral therapy, 239–240
  pharmacologic therapy, 240, 243
  medications for, 241–242t
  meta-analysis of literature on, 243
opiods used for, 74
other local oral factors and, 234–235
possible salivary and serologic biomarkers of, 237
primary and secondary, 236t
prognosis, 234
psychological factors related to, 235–237
quantitative sensory testing in, 233–234
  blink reflex testing, 233–234
  chorda tympani, taste, and, 234
metallic dysguesia, 234
neurosensorial threshold testing, 233
  taste threshold changes and, 234
recommendations on diagnosis and treatment of, 243–244
subpopulations of patients with, 233
epidemiology, 233
“Burst” ketamine therapy, 222
Buspirone, for suppressing motor disorders, 334
Butalbital
  for chronic orofacial pain, 37
Calcitonin, 320
Calcium channel blockers
  for chronic daily headaches, 263
  for cluster headaches, 265
  migraine prevention and, 37
Calcium channels, neuropathic pain and, 299
CAM. See Complementary and alternative medicine
Cancer
  co-morbidities as result of, 213–218
  limited mouth opening secondary to muscle spasm
  and contracture, 214–215
  neuropathic pain related to, 212–214
  oral neurosensory alterations
  intraoral sensory alterations, 217–218
  speech, masticatory, and swallowing deficits, 215–217
  recommendations on treating orofacial pain and
dysfunction related to, 225–226
Cancer-induced trigeminal pain, 98–99
  clinical criteria, 98
  diagnostic procedures, 99
  etiology, 98
  treatment methods, 99
Cancer pain
  adjuvant analgesics, 219, 223
  anticonvulsant drugs, 220
  commonly used, 221t
  corticosteroids, 222
  ketamine and other N-methyl-D-aspartate receptor
  blockers, 220, 222
  skeletal muscle relaxants, 222–223
  tricyclics, SSRIs, and SNRI antidepressants, 220
  anesthetic management, 223–224
  cannabinoids, 224
  challenges in management of, 218–219
  NSAIDs and nonopioid analgesics, 219
complementary and alternative medicine, 224–225
in jaw
clinical criteria, 22
confirmatory or exclusionary diagnostic methods, 9r
distinguishing clinical features, 5r
etiology of, 8r, 22
neurosurgical procedures in orofacial region, 224
opioids for, 76
modifications to WHO analgesic ladder for management of, 223
orofacial pain and, 6
severe and refractory, intravenous, intrathecal, or epidural delivery of opioids for, 79
Cancer pain management, barriers to, 218–219
Cancer patients, prevalence of pain in, 212
Cancer-related perineural invasion, 95
Cancer therapy, oral mucositis and, 184
Candesartan, for chronic daily headache or chronic migraine, 260, 263–264
Cannabinoid receptor 1 (CB1), cancer pain and, 224
Cannabinoids, cancer pain management and, 224, 226
Cannabis medical extract, cancer pain management and, 224
Caphosol, 189, 203
Capsaicin cream for TMJ arthritis, 317, 318
intraoral, 156
topical, 89–90
Capsulitis, 13
NSAIDs for, 157
Carbamazepine, 77, 108
for chronic orofacial pain, 35–36
description, mechanism of action, and primary indications, 100
as a diagnostic test for orofacial pain, 160–161
Medline search: classification, orofacial pain, facial pain, pain, 31r
recommendations for neurogenous and neuropathic pain, 108
side effects and adverse drug reactions, 100–101
starting dose, 100
for SUNCT, 252
trigeminal neuralgia and efficacy of, 101–102
Carbi/levodopa, for childhood onset dystonias, 334
Cardiotoxicity, NSAIDs and, 59
Carisoprodol, 39, 116
for chronic orofacial pain, 39
D- and X-level interactions with, 125r
description, mechanism of action, and primary indications, 117
efficacy for musculoskeletal pain associated spasm, 117
Medline search: classification, orofacial pain, facial pain, pain, 31r
metabolism, side effects, and adverse drug reactions, 117
for musculoskeletal pain, 158
starting dose, 117
Cartilage destruction, osteoarthritis and, 313
Cathartics, opioids and need for, 73
Captopril, metallic dysgeusia and, 234
CBC. See Complete blood cell count
CCI. See Chronic constriction injury
CDHs. See Chronic daily headaches
Ceiling effect, 77
Celecoxib, 62
adverse effects, 58
for chronic orofacial pain, 34
dosage, 58
efficacy for chronic pain, 58
indications, 58
Medline search: classification, orofacial pain, facial pain, pain, 31r
oral formulations and dosing protocol, 49r
osteoarthritis and, 58
Centers for Disease Control and Prevention, 148
opioid analgesic mortality statistics from, 75
Central inhibitory pathway deficiency, neuropathic pain and, 300–301
Central nervous system, fibromyalgia and, 12
Central sensitization
chronic myalgia or fibromyalgia and, 276
neuropathic pain and, 300
trigeminal neuropathy and, 99
Cerebello-pontine angle tumors, 96
Cerebral palsy, 330
Cerebral venous thrombosis, 249
Cervical dystonia, 333
Cervical muscles, palpating, 273
Cervical myofascial pain, muscle relaxants for, 115
Cervical plexus block, for orofacial pain, 154
Cervicogenic headaches, occipital nerve blockade and, 167
CFA. See Complete Freund’s adjuvant
Cheek chewing, 326
Cheek retractor, in anesthetic test armamentarium, 157
Chemically modified tetracyclines, antinociceptive action of, 147
Chemoreceptor trigger zone, antipsychotics, pain and, 137
Chemotherapy
for cancer, orofacial symptoms and, 213
oral mucositis and, 22, 184
Chemotherapy-induced peripheral neuropathy, 213
agent-specific signs and symptoms of, 214r
Chewing deficits, in head and neck cancer patients, 215–217
Children, bruxism in, 330
Chin paresthesia, systemic cancer and, 218
Chin-to-chest stretch, 280
Chiropractic
  cancer pain and, 226
  for fibromyalgia or myalgia, 280
Chloroxazone, 116
Chlorhexidine rinses, oral mucositis management and, 188
Chlorzoxazone
  D- and X-level interactions with, 125
  description, mechanism of action, and primary indications, 118
  efficacy for musculoskeletal pain associated spasm, 118–119
  metabolism, side effects, and adverse drug reactions, 118
  for musculoskeletal pain, 158
  starting dose, 118
Cholecystokinin, 84
Chondroitin sulfate, 311
  for TMJ arthritis, 315–316
Chorda tympani
  dysfunction of, burning mouth syndrome and, 238
  taste, burning mouth syndrome and, 234
Chronic abortive treatment, for migraines, 256–257
Chronic constriction injury, minocycline and, 146
Chronic daily headaches, 257–258, 305
  aspirin for, 53
  behavioral treatment supplement for, 265
  botulinum toxin and, 175
  classification of, 258r
  clinical criteria for, 17
  complementary and alternative medicine for, 265–266
  confirmatory or exclusionary diagnostic methods, 9t
  diagnosis algorithm for, 258
  disability and long-term prognosis with, 266
  distinguishing clinical features of, 5t
  etiology of, 7t, 17
  hemicrania continua, 258
  hospitalization for, 266
  medication overuse headache, 259
  methylprednisolone and prednisone and, 61
  new daily-persistent headache, 259
  pathogenesis of, 259
  prevalence of, 257
  preventative therapy for, 260r
  primary, defined, 257
  recommendations for diagnosis and treatment of, 266–267
  risk factors for, 257
  treatment protocols for, 259–266
  anticonvulsants, 261–262
  antihypertensives, 262–264
  botulinum toxin, 264
  indomethacin as abortive headache agent, 260
  SSRIs, 264
  starting preventative medication for, 260
  tricyclic antidepressants, 260–261
  withdraw symptomatic medication, 259–260
Chronic joint dysfunction, recommendations for, 351
Chronic migraine, 257
  preventative therapy for, 260r
Chronic nerve constriction injury, etodolac and, 59
Chronic orofacial pain
  cautionary approach to current literature on, 30, 32
  description of, 29
  managing, top 60 medications for, 29–30
  nonopioid analgesics for, 62
  recent literature on pharmacologic treatment of, 30
Chronic pain. See also Antibacterial agents as analgesics in chronic pain; Pharmacologic agents for chronic pain; Psychopharmacologic agents for chronic pain
  tramadol for, 51
Chronic paroxysmal hemicrania, 161
Chronic tension-type headache, 17, 257
  botulinum toxin and, 175–176
Chronic trigeminal neuropathy
  clinical characteristics of, 296–298
  atypical odontalgia, 296–297
  nerve compression, 297
  neuropathic pain, 297
  phantom tooth pain, 297
  TMJ pain, 297
  confirmatory or exclusionary diagnostic methods, 9t
  defining, 296
  diagnosing and managing, 295–306
  distinguishing clinical features, 5t
  final recommendations for, 306
  history and prior terminology, 296
  long-term prognosis for, 305–306
  neuropathic pain mechanisms, 298–301
  central inhibitory pathway deficiency, 300–301
  central sensitization and plasticity, 300
  demyelination of nerves, 299
  increased sympathetic to afferent sensory neuron activity, 300
  local nerve injuries, 299
  nerve sprouting and ectopic neural activity, 299
  peripheral sensitization, 299–300
  prevalence of, 295–296
  psychiatric co-morbid disease, 298
  treatment of, 304–305
    first-line treatment for, 305
    fourth-line treatment for, 305
    second-line treatment for, 305
    third-line treatment for, 305
Chronic trigeminal neuropathy sympathetically maintained, key features of, summary, 96t
Chronic trigeminal pain
differential diagnosis of, 301–303
anesthetic challenge test in neuropathy diagnosis, 302–303
lidocaine inefficacy in neuropathy, 301–302
in otherwise healthy tooth, etiology of, 303–304
clenching-induced pulpitis, 303–304
incomplete tooth fractures, 304
Chronic widespread pain, fibromyalgia and, 11–12
CHs. See Cluster headaches
Cicatricial pemphigoid, orofacial pain due to, 20
Cisplatin, signs/symptoms of peripheral neuropathy and, 214t
Cisplatinum
neuritis/neuropathies and, 98
medication-induced, 18
Citalopram
for chronic orofacial pain, 38–39
extrapyramidal reactions and, 337
Medline search: classification, orofacial pain, facial pain, pain, 31t
for myofascial pain and fibromyalgia, 282t
for pain control: FDA approval, off-label use, dose, 130t
for pain suppression, 134
Clenching. See Tooth clenching
Click 4 Drugs, 78
Clicking, DDWR and strict avoidance of, 348
Clobetasol propionate, 200
Clomipramine, 77
for pain control: FDA approval, off-label use, dose, 130t
for pain suppression, metabolism, side effects and adverse drug reactions, 133
Clonazepam, 39, 116
for bruxism, 332
for burning mouth syndrome, 240
for chronic orofacial pain, 40–41
efficacy for musculoskeletal pain associated spasm, 123
Medline search: classification, orofacial pain, facial pain, pain, 31t
oral and topical, for burning mouth syndrome, 241t, 244
Clonidine, 79, 86
for suppressing motor activity, 334
topical, for neuropathic pain, 90
Clonidine patches, 90
Closed locking. See Disk displacement with no reduction
Clostridium botulinum, 40, 169
Clozapine
oral tardive dyskinesia and, 23
tardive dystonia and dyskinesia and, 335
Clozaril, oral tardive dyskinesia and, 23
Cluster headaches, 38
acute treatments for, 257t
autonomic cephalalgias and etiology of, 7t
chronic, 17
confirmatory or exclusionary diagnostic methods, 8t
criteria for, 16, 251t
distinguishing clinical features of, 5t
etiology of, 16
features of, 252t
preventative treatments for, 265
CM. See Chronic migraine
CME. See Cannabis medical extract
CMTs. See Chemically modified tetracyclines
CNS. See Central nervous system
CNS pain pathway, burning mouth syndrome and, 239
Cocaine, 78
extrapyramidal reactions and, 337, 339
Cocainization of sphenopalatine ganglion, for cluster headaches, 257, 257t
Cochrane Database, 87
Codeine, 66
adverse effects, 68
for chronic orofacial pain, 32
dosage, 68
efficacy for acute pain, 68–69
efficacy for chronic pain, 69
indications, 68
Medline search: classification, orofacial pain, facial pain, pain, 31t
oral and topical, for burning mouth syndrome, 241t, 244
for noncancer pain, 74
Cognitive behavioral therapy, for burning mouth syndrome, 239–240, 244
Cold applications, masticatory myoogenous pain and, 278
Common Terminology Criteria for Adverse Events, oral mucositis scale, 184
Complementary and alternative medicine
for cancer pain management, 224–225
for cluster headaches, 265–266
Complete blood cell count, burning mouth syndrome and, 236t
Complete Freund’s adjuvant, 138
Condyle open locking and dislocation, 343
Condyles, 311
simple open locking and, 13
tissue-engineered, 321
Cone beam CT, internal derangement and, 346t, 347
Confirmatory diagnostic methods, 8t–9t
Connective tissue disorders
facial pain and, 14–16
trigeminal sensory neuropathy and, 15
Conotoxins, 299–300
Constipation management, opioids and, 73
Contingent feedback devices, for bruxism, 332
Coronoidectomy, 215
Corticosteroid creams, for TMJ arthritis, 317–318
Corticosteroid injections, for TMJ arthritis, 316
Corticosteroid medications, 59–61
cancer pain management and, 221r, 222, 226
for chronic orofacial pain, 34–35
for cluster headaches, 265
intra-auricular, as diagnostic test for inflammation, 158
intralesional injection of
adverse effects, 200
indications and dosing, 200
potency, 200
for noninfectious and non-neoplastic ulcers
adverse effects, 199
potency of, 199
oral formulations and dosing protocol, 49t
for orofacial pain, 156–158
systemic
adverse effects, 201
indications and dosing, 200–201
potency, 201
Corticosteroid potency table, 199t
COX-1, 156
COX-2, 77, 156
COX-2 selective NSAIDs, 34
oral formulations and dosing protocol, 49t
Cranial nerve (CN) neuralgias, 96–97
clinical criteria for, 97
diagnostic procedures for, 97
etiology of, 97
treatment methods for, 97
Craniomandibular muscles, how to palpate, 271–273
Crepitus, 321
disk displacement with no reduction and, 12
disk displacement with reduction and, 12
Crohn’s disease, metallic dysgeusia and, 234
Cryoneuroablation, for orofacial pain, 169
Cryoprobes, neuromas and treatment with, 99
Cryotherapy, 189, 279
CTCAE. See Common Terminology Criteria for Adverse Events
CTTH. See Chronic tension-type headache
CTZ. See Chemoreceptor trigger zone
Cyber Chase, 78
Cyber Rx, 78
Cybex Isokinetic Dynamometer, 120
Cyclic neutropenia, causation, 197
Cyclobenzaprine, 116
for chronic orofacial pain, 39
D- and X-level interactions with, 125t
for DDNR, 349
description, mechanism of action, and primary indications, 117
for fibromyalgia, efficacy of, 283
Medline search: classification, orofacial pain, facial pain, pain, 31t
metabolism, side effects, and adverse drug reactions, 117
for musculoskeletal pain association spasm, efficacy of, 117–118
for myofascial pain and fibromyalgia, 287–288
starting dose for, 117
Cyclobenzaprine hydrochloride, for musculoskeletal pain, 158
Cyclophosphamide, 320
Cyclosporine, 320
for autoimmune oral mucosal reaction
adverse reactions, 201
indications and dosing, 201
Cylert, extrapyramidal reactions and, 339
CYP450 enzymes, SSRIs and, 135
Cytokines
in neuropathic pain, 300
oral mucositis pathogenesis and, 186–187
Cytomegalovirus
facial pain related to trigeminal neuritis and, 7t
viral-induced polyneuritis and, 18, 98
DADPS or dapsone
for autoimmune oral mucosal reaction
adverse reactions, 201
indications and dosing, 201
Dangerous (secondary) headaches, causes of, 248
Danish Health and Morbidity Survey, 75
Danish Twin Registry, 250
Dantrolene, 116
D- and X-level interactions with, 125t
description, mechanism of action, and primary indications, 122
efficacy for musculoskeletal pain associated spasm, 123
metabolism, side effects, and adverse drug reactions, 122–123
starting dose, 122
Dapsone, medication-induced neuritis/neuropathies and, 18
Day Watch, 78
DDIs. See Drug-drug interactions
DDN. See Nonreducing displaced disk
DDNR. See Disk displacement without reduction
DDR. See Reducing displaced disk
DDWR. See Disk displacement with reduction
DEA. See Drug Enforcement Agency
Degenerative joint disease, hyaluronic acid injections for, 317
Demyelination of nerves, chronic trigeminal neuropathy and, 299
Dental abscess, 97
Dental pulpal infections, antibiotics and, 145
Dental traumatic neuropathy, capsaicin for, 90
Depakote, for chronic daily headache, 261
Depression
chronic pain and, 38
dysfunction of serotonergic and noradrenergic pathways in, 131
Dermatitis herpetiformis, orofacial pain due to, 20
Desipramine, 38
neuropathic pain disorders and, 133
for pain control: FDA approval, off-label use, dose, 130
for pain suppression, 133
Desmoglein 1, 195–196
Desmoglein 3, 195–196
Desquamative gingivitis, 22
Dexamethasone
cancer pain management and, 222
glucocorticoid potency and duration of action, 199
Dexedrine, extrapyramidal reactions and, 339
Dextroamphetamine
extrapyramidal reactions and, 337
for pain control: FDA approval, off-label use, dose, 131
Dextromethorphan, for musculoskeletal pain, 287
DHE. See Dihydroergotamine
Diabetic neuropathy, 98
capsaicin for, 90
orofacial pain and, 6
polyneuritis and, 18
Diabetic polyneuropathy
pregabalin for, 106
tramadol and, 52
Diabetic retinopathy, key features of, summary, 96
Diagnostic methods, confirmatory or exclusionary, 8r–9t
Diagnostic testing, 6
Diazepam, 116
for chronic orofacial pain, 40–41
D- and X-level interactions with, 125
description, mechanism of action, and primary indications, 123
efficacy for musculoskeletal pain associated spasm, 123–124
for flexor spasms, 121
Medline search: classification, orofacial pain, facial pain, pain, 31
metabolism, side effects, and adverse drug reactions, 123
neuropathic pain disorders and, 138
for pain control: FDA approval, off-label use, dose, 131
for recurrent neuroleptic-induced dystonic reactions, 336
starting dose, 123
Diclofenac, 86
adverse effects, 56
dosage, 56
efficacy for chronic pain, 56–57
indications, 56
oral formulations and dosing protocol, 49
Diclofenac sodium, cancer pain management and, 219
Dideoxycytidine
neuritis/neuropathies and, 98
medication-induced, 18
Dideoxyinosine, neuritis/neuropathies and, 98
Diet, for oral mucositis management, 187–188
Diethylproprion, extrapyramidal reactions and, 337, 339
Diffuse nociceptive inhibitory control, 167
Diflunisal
adverse effects, 53
dosage for, 53
efficacy for chronic pain, 53
indications, 53
oral formulations and dosing protocol for, 48
Dihydroergotamine
for chronic daily headaches, 266
for chronic orofacial pain, 37
for cluster headaches, 257
for episodic migraines, 256
Medline search: classification, orofacial pain, facial pain, pain, 31
Diphenhydramine, for suppressing motor activity, 334
Discoid lupus erythematosus, 196
Disease, defined, 3
Disease-modifying anti-rheumatic drugs
complications of, 321
for polyjoint inflammatory TMJ arthritis, 320–321
Disease-modifying arthritic drugs, 47
Disease-modifying osteoarthritis drugs, 320
Disk-condyle incoordination. See Disk replacement with reduction
Disk displacement, osteoarthritis and, 312
Disk displacement without reduction, 343
clinical manifestations of, 344
final recommendations for treatment of, 352
most efficacious interventions for, 351–352
treatment of, 348–351
anesthetic-assisted joint mobilization for, 349–350
anti-inflammatory, muscle relaxant, self-applied physical therapy for, 349
arthrocentesis for, 350
arthroscopic treatment for, 350–351
Disk displacement with reduction
avoidance therapy for, 347–348
clinical criteria for, 12
clinical manifestations of, 343–344
etiology of, 12
final recommendations for treatment of, 352
intra-articular injection of sodium hyaluronate for, 348
most efficacious interventions for, 351–352
nighttime use of lateral motion restriction appliances, 348
painful TMJ secondary to, 34
Disorder, defined, 3
Distal interphalangeal (DIP) joint, 319
Distal myocutaneous flap, speech and swallowing function
in cancer patients and, 217
Divalproex sodium, for chronic daily headache, 260t, 261
DJD. See Degenerative joint disease
DMARDs. See Disease-modifying anti-rheumatic drugs
DMOADs. See Disease-modifying osteoarthritis drugs
DNIC. See Diffuse nociceptive inhibitory control
Docusate, 73
Donepezil, for pain control: FDA approval, off-label use,
dose, 131t
Dopamine receptor alteration theory, burning mouth
syndrome and, 239
Dopamine receptor antagonists, oral tardive dyskinesia
and, 23
Dopamine therapy, for dystonia, 334
Dopa-responsive dystonias, 334
Dosing protocols
for corticosteroids, 49t
for COX-2 selective NSAIDs, 49t
for nonopioid analgesics, 48t
for nonselective NSAIDs, 48t–49t
for salicylates, 48t
Dothiepin, for fibromyalgia, efficacy of, 283
Doxepin
for fibromyalgia, efficacy of, 283
for pain control: FDA approval, off-label use, dose, 130t
for pain suppression, metabolism, side effects and
adverse drug reactions, 133
Doxycycline, 320
osteoarthritis and, 146
D-penicillamine, metallic dysgeusia and, 234
d-propxyphene, 129
DRDs. See Dopa-responsive dystonias
Dronabinol, for cancer pain management, 224
Drug Attitude Inventory scale, 85
Drug-drug interactions
for D- and X-level interactions, 125t
with muscle relaxants, 124
Drug Enforcement Agency, Internet drug trafficking
initiatives, 78
Drug-induced dystonic-type extrapyramidal reactions,
327t, 336–337
serotonergic agents and, 337
stimulant drugs and, 337
treatment of, 337
Drug-induced extrapyramidal reactions, recommendations
for, 339
Drug-induced oral ulcers
causation, 195
clinical features of, 192t
clinical presentation with, 195
etiology of, 193t
Dry mouth, burning mouth syndrome and, 20
Duloxetine, 42, 77
for burning mouth syndrome, 242t, 244
for cancer pain management, 220
for chronic orofacial pain, 38
for chronic trigeminal neuropathy, 305
for fibromyalgia
efficacy of, 284
use of, 140
Medline search: classification, orofacial pain, facial
pain, pain, 31t
for myofascial pain and fibromyalgia, 282t
for pain control: FDA approval, off-label use, dose,
130t
for pain suppression, starting dose, 134
Duragesic, 71
Dysfunction, defined, 3
Dysgeusia, burning mouth syndrome and, 233, 234,
243
Dyskinesia, 22, 116, 326
clinical criteria, 23
drug-induced, 335
etiology of, 8t, 23
oral, 335–336
Dysport, 170
Dystonia, 116, 326
clinical criteria for, 23
etiology of, 8t, 23
focal forms, prevalence of, 333
oromandibular, 333–335
Dystonic reactions, extrapyramidal syndrome reaction and,
336
Eastern Cooperative Oncology Group (ECOG), 184
Ecstasy, 78
extrapyramidal reactions and, 337, 339
Ectopic neural activity, nerve sprouting and, 299
EFNS. See European Federation of Neurological Sciences
ELA2, cyclic neutropenia and, 197
Elderly patients
   opioids for cancer pain management in, 223
   persistent pain in, 9
   TMJ arthritis in, 312
Elderly women, tardive dyskinesia and, 335
Electrical acupuncture, 164
Electrical neuromodulation, cancer-related pain and, 224
Electromyography
   muscle activity recording with MRE vs., 115
   recording of masseter muscle activity, 326, 327, 328, 329, 330
Eletriptan
   for chronic orofacial pain, 36–37
   for episodic migraines, 256
   Medline search: classification, orofacial pain, facial pain, pain, 31r
EM. See Erythema multiforme
EMLA. See Eutectec mixture of local anesthetic
EMLA cream, 35
Emugel, 88
Endocannabioids, cancer pain and, 224
Eosinophilic ulcers
   causation, 198
   clinical features of, 192r
   clinical presentation with, 197
   etiology of, 193r
Episodic headaches, 248, 254
   chronic, acetaminophen and, 50, 51
   over-the-counter medications and, 254–255
Episodic migraines, acute abortive treatment for, 256
Episodic tension-type headaches, 17, 250, 259r
   avoidance checklist, 255r
   trigger-point and other injections for, 255–256
   triggers for, 255
Ergot alkaloids, for episodic migraines, 256
Ergotamine
   for chronic daily headaches, 17
   for cluster headaches, 257, 257r
Erosion, ulcers vs., 191
Erosive lichen planus, 35
   clinical features of, 5t, 192r
Erythema multiforme
   causation, 194
   clinical features of, 192r
   clinical presentation with, 194
   etiology of, 193r
   modafinil and, 139
   toxic epidermal necrolysis, 194
Erythema multiforme major, 194
Erythema multiforme minor, 194
Escitalopram
   for chronic orofacial pain, 38–39
   extrapyramidal reactions and, 337
   Medline search: classification, orofacial pain, facial pain, pain, 31r
   for pain control: FDA approval, off-label use, dose, 130r
   for pain suppression, 134
Etidocaine, trigger-point injections for orofacial pain, spasm and, 165
Etiologies, determining, 276–277
Etodolac, 34, 62
   adverse effects, 59
   dosage, 59
   efficacy for chronic pain, 59
   indications, 59
   oral formulations and dosing protocol, 49t
ETTHs. See Episodic tension-type headaches
European Federation of Neurological Sciences, 38, 87, 96, 124
European Pain Task Force, 42
Eutectec mixture of local anesthetic, 87
Exclusionary diagnostic methods, 8t–9t
Exercise
   for masticatory myogenous pain, 280
   opioids and need for, 73
   TMJ arthritis and, 315
Experimental pain in humans, botulinum toxin and, 172–173
Extrapyramidal reactions, drug-induced dystonic type, 336–337
Facial pain
   autoimmune arthritis, connective tissue, and vascular disorders related to, 14–16
   chronic trigeminal neuropathy and, etiology of, 7t
   due to derangement and non-autoimmune arthritis/or capsulitis of TMJ, 12–16
   postherpetic neuralgia and, etiology of, 8t
   related to chronic oral inflammatory disease, 20–22
   related to chronic trigeminal neuropathy, 18–19
   related to muscle pain, 9–12
   related to oral motor disorders, 22–24
   related to postherpetic neuralgia, 19
   related to trigeminal neuralgia, 18
   related to trigeminal neuroma, 18
   trigeminal neuralgia and, etiology of, 7t
   trigeminal neuritis and, etiology of, 7t
   trigeminal neuroma and, etiology of, 7t
Fasciocutaneous radial forearm flaps, sensory recovery in cancer patients and, 218

Fentanyl, 76
adverse effects of, 71

cancer pain management and, 223
dosage of, 71
efficacy for acute pain, 71
efficacy for chronic pain, 71
indications for, 71

Fentanyl patch, 78

Fentanyl transdermal therapeutic system, oral mucositis and, 188

Fibrillation, 313

Fibromyalgia, 9
aerobic exercise for, 280, 281
amitriptyline and, efficacy, 133
anticonvulsants and, efficacy, 286
antipsychotics and, 137

central sensitization and, 276
chronic widespread pain and, 11–12
clinical criteria, 11–12
etiology of, 12
confirmatory or exclusionary diagnostic methods for, 8r
diagnostic criteria for, 273
distinguishing clinical features of, 4r
etiology of, 7t
medications for, 282r

muscle relaxants and sedative agents for, efficacy, 288
NMDA receptor antagonists for, efficacy, 287
norepinephrine reuptake inhibitors and, 136

NSAIDs for, efficacy, 285

opioids for, efficacy, 286

orofacial pain and, 6

pregabalin for, efficacy, 286

selective serotonin reuptake inhibitors for, 135, 284

serotonin and norepinephrine reuptake inhibitors for, 134, 284

stimulants and, 139
topical medications for, 283

tramadol for, 52, 285–286

tricyclic antidepressants for, efficacy, 133, 283–284

widespread chronic muscle pain and, 273–274, 273t

Fibromyalgia syndrome, 9

Fibrositis, 60

Fludrocortisone acetate, glucocorticoid potency and duration of action, 199t

Flucinonide
for chronic orofacial pain, 34–35

Medline search: classification, orofacial pain, facial pain, pain, 31t

Flucinonide 0.05%, for noninfectious and non-neoplastic ulcers, 199

Fluoxetine, 68
for chronic orofacial pain, 38–39
extrapyramidal reactions and, 337

Medline search: classification, orofacial pain, facial pain, pain, 31t

motor side effects with, 24

for pain control: FDA approval, off-label use, dose, 130r

for pain suppression, starting dose, 134

Fluphenazine

neuropathic pain disorders and, 137

for pain control: FDA approval, off-label use, dose, 130r

Fluvoxamine
extrapyramidal reactions and, 337

for pain control: FDA approval, off-label use, dose, 130r

for pain suppression, 134

FM. See Fibromyalgia

fMRI. See Functional MRI

FMS. See Fibromyalgia syndrome

Focal chronic orodental neuropathic pain, botulinum toxin and, 176

Focal dystonias, 23

Focal myalgia due to direct trauma, criteria, 273t

Food and Drug Administration, 66
botulinum toxin type A approval, 40, 169

tramadol approved by, 32

Fractured teeth, incomplete, in chronic trigeminal pain, 304

Frequent episodic tension-type headache, 250t

Frovatriptan (Frova)
for chronic orofacial pain, 36–37
for episodic migraines, 256

Medline search: classification, orofacial pain, facial pain, pain, 31t

FTTS. See Fentanyl transdermal therapeutic system

Functional MRI, orofacial pain and, 151

Fungiform papillae innervations, increased, burning mouth syndrome and, 238

GABA. See Gamma-aminobutyric acid

GABA-A, 138

GABA agonist, for cancer pain management, 221t

GABA-B, 138

GABA-C, 138

GABA-ergic drugs, for chronic orofacial pain, 40

Gabapentin, 38, 42, 77, 101, 102
for burning mouth syndrome, 240, 241r
cancer pain management and, 220
for chronic daily headache or chronic migraine, 260r, 262
for chronic orofacial pain, 36
for chronic trigeminal neuropathy, 305
description, mechanism of action, and primary indications, 104–105
FDA-approved for epilepsy and neuropathic pain, 119
Medline search: classification, orofacial pain, facial
pain, pain, 31
neuromas and treatment with, 99
for neuropathic pain, 286, 289
neuropathic pain disorders and efficacy of, 105
for painful diabetic neuropathy, 108
side effects and adverse drug reactions, 105
starting dose, 105
for SUNCT, 252
therapeutic drug monitoring for, 108
trigeminal neuralgia and efficacy of, 105

Gait. See Glucosamine/chondroitin Arthritis Intervention
Trial
Gamma-aminobutyric acid, 36
Gastro-esophageal reflux disorder, 316
Gebauer’s Spray and Stretch, 159
Gelclair, 189, 203
Gender
bruxism and, 24
burning mouth syndrome and, 20, 235
chronic daily headaches and, 257
cluster headaches and, 16
dyskinesias and, 22
episodic tension-type headache and, 250
fibromyalgia and, 11
giant cell arteritis and, 15
masticatory myofascial pain and, 10
migraines and, 16, 250
paroxysmal hemicrania and, 252
pemphigoid and, 21
tardive dyskinesias and, 23, 335
Generalized osteoarthritis, 319
Geniculate neuralgia, 97
Geographic tongue, 235
GERD. See Gastro-esophageal reflux disorder
Geste antagoniste, 333
Giant cell arteritis, 15, 249
GI events, NSAIDs and, 54
Glossodynia, 232
Glossopharyngeal neuralgia, 97
key features of, summary, 96
Glossopyrosis, 20, 232
Glucosamine, for TMJ arthritis, 315–316
Glucosamine/chondroitin Arthritis Intervention Trial, 315
Glutamine, reducing severity of oral mucositis with, 191
GlycoLax, 73
GOA. See Generalized osteoarthritis
Gold, intramuscular, 320
Graft-versus-host disease, 35
oral and pharyngeal mucositis secondary to, 213
orofacial pain due to, 20
Graft-versus-host disease-induced oral ulcers, special case
treatment of, 202–203
Granulocyte-macrophage colony stimulating factor,
reducing severity of oral mucositis with, 190
Guaiifenesin, 119
Guided imagery, cancer pain and, 226
Guillain-Barré syndrome, 18, 98
Gum chewing, 315, 326
GVHD. See Graft-versus-host disease

Habitual parafunction and secondary hypertonicity,
etiology of, 8r
Habitual parafunction and secondary masticatory
hyperactivity, distinguishing clinical features of, 6r
HADS. See Hamilton’s Depression and Anxiety Scales
Hallucinogens, 78
Haloperidol, for pain control: FDA approval, off-label use,
dose, 130
Hamilton’s Depression and Anxiety Scales, 236, 237
HC. See Hemicrania continua
Headaches, 248–267
avoidance checklist, 255, 255r
chronic daily, 257–259
classification, 258r
disability and long-term prognosis, 266
hemicrania continua, 258
hospitalization for, 266
medication overuse headache, 259
new daily-persistent, 259
pathogenesis of, 259
recommendations for diagnosis and treatment of,
266–267
complementary and alternative medicine for, 265–266
dangerous, 248–250
brain tumor headache, 249
meningitis headache, 249
post-traumatic, 250
secondary abscess, 250
in stroke syndromes, 249
subarachnoid hemorrhage headaches, 248–249
temporal arteritis (giant cell arteritis), 249
episodic
cluster headaches and other trigeminal autonomic
cephalalgias, 251–252
frequent tension-type, 250r
infrequent tension-type, 250r
migraine with or without aura, 250–251
paroxysmal hemicrania, 252
short-lasting neuralgiform headache with conjunctival
injection and tearing, 252
tension-type headache, 250
episodic headache treatment, 254–257
Headaches (cont’d)
  acute abortive treatment for cluster headache, 257
  chronic abortive treatments, 256–257
  for episodic migraines, 256
  headache avoidance checklist, 255
  myofascial-based treatment, 255
  over-the-counter medications, 254–255
  trigger-point and other injections for migraine, ETTH, and TAC, 255–256
  etiology of tension-type headaches, 253–254
  jaw muscle activity, 253
  myofascial pain, 253–254
  fibromyalgia and, 11
  forms of, 248
  giant cell arteritis and, 15
  indomethacin-responsive, 161
  occipital nerve block for, 166–167
  orofacial pain and, 16–17
  chronic daily headaches, 17
  cluster headaches and autonomic cephalalgias, 16
  migraine, 16
  tension-type headaches, 16–17
  other primary, 252, 253
  pathogenesis of migraine, 254
  pathogenesis of trigeminal autonomic cephalalgias, 254
  prevalence of, 16
  treatment protocols for chronic daily, 259–266
  anticonvulsants for, 261–262
  antihypertensives for, 262–264
  behavioral treatment supplement, 265
  botulinum toxin, 264
  indomethacin as abortive headache agent, 260
  preventative for cluster headache, 265
  SSRIs, 264
  starting preventative medication for, 260
  tricyclic antidepressants for, 260–261
  withdraw symptomatic medication, 259–260
Head and neck cancer
  anesthetic management, cancer pain and, 223–224
  recurrent, severe orofacial pain and, 213
  speech, masticatory, and swallowing deficits with, 215–217
Head and neck posture, proper, for masticatory myogenous pain, 278
Healing phase, oral mucositis pathogenesis, 186, 186
Heat packs, for TMJ arthritis, 315
Heberden’s nodes, polyjoint osteoarthritis and, 14, 319
Hematopoietic stem cell transplantation, oral mucositis and, 184
Hemicrania continua, 17, 41, 161, 257, 258
Hemifacial spasm
  BoNT/A injections for, 178
  botulinum toxin and, 172
Hemimasticatory spasm, botulinum toxin and, 172
Hemiplegic migraine, 16, 251
Hepatic toxicity, acetaminophen and, 50
Hepatitis B
  vasculitic neuropathy and, 18
  viral-induced polyneuritis and, 98
Hepatitis C
  vasculitic neuropathy and, 18
  viral-induced polyneuritis and, 98
Herbal therapy, cancer pain and, 226
Heroin, 78
Herpes zoster infection, 97
  mononeuritis pain and, 17
  postherpetic neuralgia and, 19
Herpetiform aphthae, 197
HIV. See Human immunodeficiency virus
HIV-related neuropathy, lamotrigine and, 103, 104
HLA-DR1, rheumatoid arthritis and, 15
HLA-DR4, rheumatoid arthritis and, 15
Hospitalization, for chronic daily headache, 266
Hot pack therapy, for masticatory myogenous pain, 279
Human immunodeficiency virus, viral-induced polyneuritis and, 18, 98
Hyalgan, 317
Hyaluronic acid injections, for TMJ arthritis, 316–317
Hydrocodone, 66
  adverse effects, 67
  for burning mouth syndrome, 242
  for chronic orofacial pain, 32
  dosage, 67
  efficacy for chronic pain, 67–68
  indications, 67
  Medline search: classification, orofacial pain, facial pain, pain, 31
Hydrocollator bags, for hot pack therapy, 279
Hydrocortisone (cortisol), glucocorticoid potency and duration of action, 199
Hydromorphone
  adverse effects, 72
  for cancer pain, 76, 223
  efficacy for acute pain, 72
  efficacy for chronic pain, 72
  indications for, 71
Hydroxychloroquine, 320
Hyperkinetic disorders, 22
Hypermobility of TMJ, internal derangement and, 345–346, 345
Index

Hypnotics, 30
Hypokinetic disorders, 22
Hypothyroidism, burning mouth syndrome and, 235

IAN. See Inferior alveolar nerve
IASP. See International Association for the Study of Pain

Ibuprofen, 69, 86
  adverse effects of, 54–55
  for chronic orofacial pain, 34
  for DDNR, 349
  dosage for, 54
  efficacy for chronic pain, 55
  indications for, 54
  Medline search: classification, orofacial pain, facial pain, pain, 31
  for myofascial pain and fibromyalgia, 282
  oral formulations and dosing protocol, 48
  for orofacial pain, 157
  preventative analgesia and, 61–62
  for TMJ arthritis, 315

Ice pack therapy
  for masticatory myogenous pain, 279
  for TMJ arthritis, 315
  “Ice-pick” headache, 161

Idiopathic chronic trigeminal neuropathy, key features of, summary, 96

Idiopathic trigeminal sensory neuropathy, 15–16
  clinical criteria for, 15
  etiology of, 7t, 15–16

IL-1
  burning mouth syndrome and, 237
  neuropathic pain and, 300

IL-2, burning mouth syndrome and, 237

IL-6, burning mouth syndrome and, 237

Imipramine, 77
  for pain control: FDA approval, off-label use, dose, 130
  for pain suppression, metabolism, side effects and adverse drug reactions, 133

Imitrex, for episodic migraines, 256

Immune-mediated neuritis, 95

Immunosuppressive agents
  for autoimmune oral mucosal reaction
    azathioprine, 202
    cyclosporine, 201
    DADPS, 201

Implantable pumps, opioid delivery via, 79

Inactive substances, differential diagnosis of orofacial pain and, 152

Incomplete tooth fractures, in chronic trigeminal pain, 304

Indomethacin
  as abortive headache agent, 260
  for chronic orofacial pain, 41
  as a diagnostic test for orofacial pain, 161
  for hemicrania continua, 258
  Medline search: classification, orofacial pain, facial pain, pain, 31
  for paroxysmal hemicrania, 252
  Inferior alveolar nerve, 301
  Infiltration anesthesia using 2% lidocaine without epinephrine, in anesthetic test armamentarium, 157

Inflammation
  neuropathic pain and, 300
  osteoarthritis and, 313

Informed consent, 84

Infrequent episodic tension-type headaches, 250

Inhalants, 78

Initiation phase, oral mucositis pathogenesis, 186, 186

Injectable steroids, as diagnostic test for inflammation, 158

Internal derangement
  description of, 343
  mechanism and etiology of, 344–346

International Association for the Study of Pain, 99, 232, 296
  Subcommittee on Taxonomy, 11

International Association for the Study of Pain
  Subcommittee on Taxonomy, 273

International Classification of Disease (version 9 [ICD-9]), 232

International Classification of Headache Disorders, 232

International Headache Society, 18, 95, 161, 248
  episodic tension-type headache
    infrequent vs. frequent, 250
    migraine categories, 251, 251
    migraine without aura criteria, 251
    secondary headache classification, 249

International Society for Oral Oncology, 184, 203

International Study Group for Behçet Disease, 196

Intra-articular morphine, for orofacial pain, 168

Intraepithelial clefing, pemphigus vulgaris and, 20–21

Intramuscular blood flow therapy, increased, masticatory myogenous pain and, 278–279

Intraoral sensory alterations, oropharyngeal cancer patients and, 217–218

Iontophoresis, topical medications for TMJ arthritis and, 317

Ipsilateral hypothalamic stimulation, for cluster headaches, 265

Irritable bowel syndrome, fibromyalgia and, 11

ISOO. See International Society for Oral Oncology
“Jabs-and-jolts” syndrome, 161
Jaw
cancer pain in, 22
distinguishing clinical features, 5
Jaw claudication, temporal arteritis and, 15, 249
Jaw derangements, dysfunction and, 13
Jaw hinge exercise, for TMJ arthritis, 315
Jaw joint clicking avoidance, 278
Jaw locking, muscle relaxants for, 115
Jaw muscle activity, as etiologic factor for episodic headaches, 253
Jaw muscle trismus, after third-molar removal, 122
Jaw pain, experimental tooth clenching, injected algesic agents and, 329–330
Jejunal flaps, sensory recovery in cancer patients and, 218
Jewish descent, pemphigus vulgaris and, 21
Joint effusion, 13
Joint lavage, for TMJ arthritis, 318–319
Joint “locking,” osteoarthritis and, 313
Joint mobilization, for DDNR, 349–350
Joint mobilization test, internal derangement and, 346
Keppra, 104
Keratinocyte growth factors, reducing severity of oral mucositis with, 190
Keratin sulfate, 311
Ketamine, 160
for cancer pain management, 220, 221, 222
for chronic orofacial pain, 41
efficacy of, 91
Medline search: classification, orofacial pain, facial pain, pain, 31
neuropathic pain disorders and efficacy of, 103–104
recommendations for neurogenic and neuropathic pain, 108
side effects and adverse drug reactions with, 103
starting dose for, 103
for SUNCT, 252
trigeminal neuralgia and efficacy of, 103
Laser therapy, low-level, reducing severity of oral mucositis with, 191
Lateral motion restriction appliance, nighttime use, for DDWR, 348
Laxatives, opioids and need for, 73
Leflunomide, 320
Leprosy, bacterial-induced polyneuritis and, 18
Levetiracetam
for cancer pain management, 220
for chronic orofacial pain, 35–36
description, mechanism of action, and primary indications, 104
Medline search: classification, orofacial pain, facial pain, pain, 31
neuropathic pain disorders and, 104
starting dose, 104
trigeminal neuralgia and, 104
Levomethorphan, 129
Levorphanol, 129
cancer pain management and, 223
Levosulpiride, for burning mouth syndrome, 243
Lichen planus, 235
burning mouth syndrome and, 239
causation, 195
clinical criteria for, 21
clinical presentation with, 195
confirmatory or exclusionary diagnostic methods, 9
etiolo of, 8, 21, 193
Lidocaine, 42, 85
auriculotemporal nerve block and use of, 152, 152, 153
for chronic orofacial pain, 35
description, mechanism of action, and primary indications, 107
Medline search: classification, orofacial pain, facial pain, pain, 31
neuropathic pain disorders and efficacy of, 107–108
postherpetic neuralgia treated with, 98
side effects and adverse drug reactions with, 107
starting dose, 107
for SUNCT, 252
topical, 87
for burning mouth syndrome, 241
recommendations for neurogenic and neuropathic pain, 108
trigger-point injections and use of, 154
Lidocaine challenge test, for diagnostic-predictive purposes, 159–160
Lidocaine 5% patch
  anesthetic management, cancer pain and, 224
  for postherpetic neuralgia, 158
  for TMJ arthritis, 318
Lidocaine 4–10% nasal spray, for cluster headaches, 257
Lidocaine inefficacy, in neuropathy, 301–302
Lidocaine infusion therapy, for nonmalignant neuropathic pain, 224
Lidocaine syringe, in anesthetic test armamentarium, 157
Lidoderm, 35
Lightning Strike, 78
Limited mouth opening
  cancer, cancer treatment and, 214–215
  Therabite used for, 214–215, 215
tongue blade therapy for, in cancer patients, 216
Limited opening testing
  skeletal muscle relaxant use in orofacial pain, 158–159
  TMJ joint injection, 159
  vapocoolant sprays used for diagnostic purposes, 159
Linear dermatosis, orofacial pain due to, 20
Lisinopril, for chronic daily headache or chronic migraine, 260, 263–264
Lithium, for cluster headaches, 265
Lithium carbonate, metallic dysgeusia and, 234
Liver damage, acetaminophen and, 50
LLLT. See Low-level laser therapy
Local anesthetics for orofacial pain, 35, 152–156
  auriculotemporal nerve block, 152–153
  right-sided, using 2% lidocaine without epinephrine, 153
  setup for, 152
cervical plexus block, 154
local anesthetic blocks for trigeminal neuralgia pain, 154
occipital nerve block, 153–154
sphenopalatine ganglion block, 153
stellate ganglion block, 153
topical anesthetic challenge test in neuropathic pain diagnosis, 154–156
trigger-point injections, 154
Localized nerve trauma, 95
Local myalgia, 9
Local nerve injuries, neuropathic pain and, 299
Local temporomandibular joint arthritis, 13–14
  clinical criteria for, 13
t distinguiishing clinical features with, 4t
etiology of, 13–14
Locking pattern, internal derangement and, 346
Locking problems, in temporomandibular joint, 12–13
Lorazepam, 116
efficacy for musculoskeletal pain associated spasm, 123
for pain control: FDA approval, off-label use, dose, 131
Lower motor neurons, 116
Low-level laser therapy, reducing severity of oral mucositis with, 191
LP. See Lichen planus
LSD, for cluster headaches, 265
Lumiracoxib, 34
Lupus erythematosus
  clinical features of, 192
t etiology of, 193
t oral ulcers associated with causation, 196
  clinical presentation, 196
sensory neuropathy and, 14
Lyme disease, 320
  bacterial-induced polyneuritis and, 18
  facial pain related to trigeminal neuritis and, 7t
  viral-induced polyneuritis and, 98
Lyrica, 105–106
Macrolides, 42
Macrotrauma, internal derangement and, 345, 345
“Magic” mouthwash
  morphine mouthrinse vs., in oral mucositis management, 189
oral mucositis management and, 188
Magnetic resonance elastography, muscle activity recording with electromyography vs., 115
Magnetic resonance image, 6
Maprotiline, for pain control: FDA approval, off-label use, dose, 130
MASCC. See Multinational Association of Supportive Care in Cancer
Massage, for fibromyalgia or myalgia, 280
Masseteric hypertrophy, botulinum toxin and, 171
Masseter muscle activity, EMG recording of, 326, 327
Mastectomy patients, pain experienced by, post-surgery, 214
Masticatory deficits, in head and neck cancer patients, 215–217
Masticatory myofascial pain, 10
  chronic, self-reported clenching and, 275
  muscle relaxants for, 115
Masticatory myogenous pain, 271
  behavioral treatment for chronic muscle pain, 281–282
  office-based medicine treatment, 280–281
  pharmacologically based treatment, 282–288, 282
  anticonvulsants, 286
  muscle relaxants and sedative agents, 287–288
  NMDA receptor antagonists, 286–287
Masticatory myogenous pain (cont’d)
   NSAIDs, 284–285
   opioids, 286
   selective serotonin reuptake inhibitors, 284
   topical medications for musculoskeletal pain, 283
   tramadol, 285
   tricyclic antidepressants, 283–284
   recommendations on diagnosis/treatment of, 288–289
   self-directed treatment
   avoidance therapy, 278
   exercise therapy, 280
   increased intramuscular blood flow therapy, 278–279
   stretch therapy, 279–280
   treatment of, 277–288
Matrix metalloprotein inhibitors, 147
Maxalt, for episodic migraines, 256
Maximal voluntary contraction, 328, 329
McGill Pain Questionnaire, 240
MCTD. See Mixed connective tissue disorders
MDMA, extrapyramidal reactions and, 337, 339
Meclofenamate sodium
   adverse effects with, 56
   dosage for, 56
   efficacy for chronic pain, 56
   indications for, 56
   oral formulations and dosing protocol, 49t
Medication delivery systems, for topical agents in
   orofacial region, 91
Medication-induced myalgia, 275
Medication-induced neuritis and neuropathies, 18, 98
Medication-overuse headaches, 61, 254, 259, 259t
Meditation, cancer pain and, 226
Mediterranean descent, pemphigus vulgaris and, 21
Medline, 87
Meige’s syndrome, 23, 172, 333, 335
Melatonin, for cluster headaches, 265
Meloxicam, 62
   adverse effects with, 59
   for chronic orofacial pain, 34
   dosage for, 58
   efficacy for chronic pain, 59
   indications for, 58
   Medline search: classification, orofacial pain, facial
   pain, pain, 31t
   oral formulations and dosing protocol, 49t
Men
   bruxism in, 24
   cluster headaches and, 16
   dyskinesias and, 22
   migraines and, 16, 250
   paroxysmal hemicrania in, 252
   pemphigoid and, 21
Meningitis headache, 249–250
Menopause, burning mouth syndrome and, 235
Mental neuropathy, systemic cancer and, 218
Meperidine, cancer pain management and, 223
Meridians, acupuncture and, 164
Metallic dysgeusia, burning mouth syndrome and, 234,
   243
Metalloproteinase inhibitors, 320
Metatarsophalangeal (MTP) joint, 319
Metaxalone, 116
   for chronic orofacial pain, 39
   D- and X-level interactions with, 125t
   description, mechanism of action, and primary
   indications, 118
   efficacy for musculoskeletal pain associated spasm, 118
   Medline search: classification, orofacial pain, facial
   pain, pain, 31t
   metabolism, side effects, and adverse drug reactions,
   118
   for musculoskeletal pain, 158
   starting dose, 118
Methadone, 129
   adverse effects, 72–73
   cancer pain management and, 76, 223
   for chronic orofacial pain, 32
   dosage for, 72
   efficacy for acute pain, 73
   efficacy for chronic pain, 73
   hazards with, 75
   indications for, 72
   Medline search: classification, orofacial pain, facial
   pain, pain, 31t
   for noncancer pain, 74
   opioid tolerance and use of, 78
   Methamphetamine, extrapyramidal reactions and, 337, 339
   Methemoglobinemia, 87
   Methicillin-resistant Staphylococcus aureus, CDC statistics
   on, 148
   Methocarbamol, 116
   for chronic orofacial pain, 39
   D- and X-level interactions with, 125t
   description, mechanism of action, and primary
   indications, 119
   efficacy for musculoskeletal pain associated with spasm,
   119
   Medline search: classification, orofacial pain, facial
   pain, pain, 31t
   metabolism, side effects, and adverse drug reactions,
   119
   for musculoskeletal pain, 158
   starting dose, 119
   Methotrexate, 320
Methylphenidate
extrapyramidal reactions and, 337, 339
for pain control: FDA approval, off-label use, dose, 131t

Methylprednisolone, 62, 201
adverse effects, 60
chronic daily headaches, 61
chronic musculoskeletal pain, 60–61
for chronic orofacial pain, 34–35
dosage, 60
efficacy for chronic pain, 60
glucocorticoid potency and duration of action, 199t
indications, 60
Medline search: classification, orofacial pain, facial pain, pain, 31t
neuropathic pain, 61
oral formulations and dosing protocol, 49t
rheumatoid arthritis, 60
Methylprednisolone acetate, for cluster headaches, 265
Metoclopramide, tardive dystonia/EPS and, 336
MI. See Motivational interviewing
Microcurrent electrotherapy, for limited mouth opening in cancer patients, 215
Microtrauma, internal derangement and, 345, 345t
Microvascular free flap, speech and swallowing function in cancer patients and, 217
Microvascular reconstructive surgery, for oropharyngeal cancer, 218
MIDAS. See Migraine Disability Assessment Score
Midface migraine, 16, 251
Migraine abortives, for chronic orofacial pain, 36–37
Migraine aura, prevalence of, 251
Migraine Disability Assessment Questionnaire, 256
Migraine Disability Assessment Score, 266
Migraine headaches
chronic, 17
botulinum toxin and, 175
clinical criteria for, 16
confirmatory or exclusionary diagnostic methods, 8t
distinguishing clinical features of, 4t
episodic, with or without aura, 250–251
etiology of, 7t, 16
orofacial pain and, 6
pathogenesis of, 254
trigger-point and other injections for, 255–256
variants, 251
Migraine medications, miscellaneous, for chronic orofacial pain, 37
Migraine without aura, IHS criteria for, 251t
Migrainous infarction, 251
Milnacipran, 38
for pain control: FDA approval, off-label use, dose, 130t
Mind-body meditation, cancer pain and, 226
Minocycline, 146
rheumatoid arthritis and, 146
Mixed connective tissue disorders, 320
Mixed mechanism pain, cancer pain as, 213
MMFP. See Masticatory myofascial pain
MMP. See Masticatory myogenous pain
MMPs. See Matrix metalloprotein inhibitors
Modafinil
adverse drug reactions, 139
for pain control: FDA approval, off-label use, dose, 131t
Modified Ashworth scale, measurement of antispasticity treatment efficacy, 120
MOH. See Medication overuse headache
Mononeuritis
etiology of, 18
onset of, 17
Morphine, 129
adverse effects, 70
alternate forms of delivery, 78–79
cancer pain management and, 76, 223
for chronic orofacial pain, 32
dosage, 69–70
efficacy for acute pain, 70
efficacy for chronic pain, 70
indications for, 69
intra-articular, for orofacial pain, 168
Medline search: classification, orofacial pain, facial pain, pain, 31t
Morphine infusion challenge test, for diagnostic-predictive purposes, 160
Morphine mouthrinse, “magic” mouthwash vs., in oral mucositis management, 189
Motivational interviewing, 84–85
Motor disorders
bruxism, 326, 327t, 330–333
drug-induced dystonic-type extrapyramidal reactions, 326, 327t, 336–337
habitual tooth clenching, 326–330, 327t
oral dyskinesia, 326, 327t, 335–336
oromandibular dystonia, 326, 327t, 333–335
Motrin, for orofacial pain, 157
Mouth and throat soreness, oral mucositis and, 186
Moxibustion, 164
MPI. See Multidimensional Pain Inventory
MPQ. See McGill Pain Questionnaire
MRE. See Magnetic resonance elastography
MRI. See Magnetic resonance image
MTrPs. See Myofascial trigger points
MTS. See Mouth and throat soreness
Mucaine, 189
Mucosal protective agents
  Caphosol, 189
  Gelclair, 189
  sucralfate, 189

Mucositis
  cancer-related, 213
  clinical criteria for, 21–22
  confirmatory or exclusionary diagnostic methods, 9t
  distinguishing clinical features of, 5t
  etiology of, 8t, 22

Mucous membrane pemphigoid
  clinical features of, 192t
  etiology of, 193t

Multidimensional Pain Inventory, 237
Multinational Association of Supportive Care in Cancer, 184, 203
Multiple sclerosis
  dystonia and, 333
  spasticity in, 120
  trigeminal neuralgia and, 96

Muscle hypoperfusion, stress-related, 275–276
Muscle pain, facial pain related to, 9–12
Muscle pain classification and causation
  diagnosis with muscle palpation, 271–273
  etiologic agents underlying myogenous pain
    central sensitization, 276
    determining etiology, 276–277
    direct muscular trauma, 274
    medication-induced myalgia, 275
    parafunction, 275
    peripheral muscle nociceptor sensitization, 276
    stress-related muscle hypoperfusion, 275–276
    trismus-induced secondary myogenous pain, 274–275
  myofascial pain, 273
    widespread chronic muscle pain and fibromyalgia, 273–274
  myogenous pain subtypes, 273–273
    myalgia due to direct muscle injury, 273
    primary local and regional myalgia, 273
    secondary local and regional myalgia, 273
    understanding, 271–277
Muscle palpation, diagnosing muscle pain with, 271
Muscle relaxants, 30
  cancer pain management and, 222–223
  for chronic orofacial pain, 39
  for DDNR, 349
  for musculoskeletal pain, 287–288
  for orofacial pain disorders, 115–119
    antispasticity drugs vs., 116
    carisoprodol, 117
    chlorzoxazone, 118
    cyclobenzaprine, 117–118
    ethocarbamol, 119
    metaxalone, 118
    orphenadrine, 119
    overview, 116
    recommendations for, 124–125
    reported adverse drug reactions for, 124
  Muscle trauma, secondary myalgia and, 10–11
Musculoskeletal disease, prevalence and costs of, 311–312
Musculoskeletal pain
  chronic
    acetaminophen and, 50–51
    methylprednisolone, prednisone and, 60–61
    tramadol for, 51–52
  drugs for relief of, 158
  topical medications for, 283
Musculoskeletal spasms, BoNT/A injections for, recommendations, 178
MVC. See Maximal voluntary contraction
Myalgia
  central sensitization and, 276
  distinguishing clinical features of, 4t
  due to direct muscle injury, 273
  local, 9
  localized, confirmatory or exclusionary diagnostic methods, 8t
  medication-induced, 275
  parafunction-induced, 275
  primary, 9–10
  primary local and regional, 273
  regional, 9
  secondary, 9, 10–11
  secondary local and regional, 273
  stress-related, 275–276
Mycosis, clinical features of, 192t
Myobloc, 169, 170
Myoclonus, 116
Myofascial-based headache treatment, 255
Myofascial pain, 273
  anxiolytics and, 138
  BoNT/A injections and, recommendations, 178
  classification of, 273
  confirmatory or exclusionary diagnostic methods, 8t
  criteria, 273t
  distinguishing clinical features of, 4t
  etiology of, 7t
  focal or regional
    clinical criteria, subjective and objective, 11
    etiology of, 11
    medications for, 282t
    NSAIDs for, 157
    opioids for, 74
    as trigger for episodic headaches, 253–254
Myofascial trigger points, 154
  botulinum toxin and, 173–174
Myogenous disorders, classifying, 271
Myogenous pain
  chronic masticatory, recommendations on diagnosis/treatment of, 288–289
  etiologic agents underlying, 274–277
  final treatment recommendations for, 288–289
  in masticatory system, categories and criteria for, 273
  subtypes of, 273–274
  trismus-induced secondary, 274–275
Myositis in jaw system, traumatic cause of, 274
Nabilone, for cancer pain management, 224
Nabumetone, 62
  adverse effects of, 57
  for chronic orofacial pain, 34
  dosage, 57
  effects for chronic pain, 57
  indications for, 57
  Medline search: classification, orofacial pain, facial pain, pain, 31
  oral formulations and dosing protocol for, 49
  for orofacial pain, 157
  for TMJ arthritis, 315
Naloxone, 129, 147
Naltrexone, oxycodone combined with, 79
Naproxen
  adverse effects with, 55
  for chronic orofacial pain, 34
  dosage for, 55
  efficacy for chronic pain, 55
  indications for, 55
  Medline search: classification, orofacial pain, facial pain, pain, 31
  oral formulations and dosing protocol, 48
Naproxen sodium, for TMJ arthritis, 315
Naratriptan, for episodic migraines, 256
Nasopharyngeal cancer, orofacial pain as first sign of, 213
National Cancer Institute, oral mucositis scale, 184
National Center for Complementary and Alternative Medicine, 225
National Fibromyalgia Association, 277
National Institute of Neurologic Disorders and Stroke, 151
National Institutes of Health, 164
NCI. See National Cancer Institute
NDPH. See New daily-persistent headache
Near infrared (NIR) spectroscopy, muscle studies with, 275
Neck cancers. See Head and neck cancers
Necrotizing sialometaplasia
  causation, 193
  clinical features of, 192
  clinical presentation with, 193
  etiology of, 193
Needle- and injection-based interventional treatments for orofacial pain, 164–169
  acupuncture, 164–165
  cryoneuroablation, 169
  intra-articular morphine and other substances, 168
  occipital nerve block for headache, 166–167
  phenol nerve block for trigeminal neuralgia, 168–169
  prolotherapy, 166
  recommendations on, 169
  sphenopalatal nerve block, 167
  stellate block, 167–168
  trigger-point injections, 165–166
Nefazodone, for pain control: FDA approval, off-label use, dose, 130
Nerve inflammation, 95
Nerve sprouting, ectopic neural activity and, 299
Nervus intermedius
  of CNVII, 97
  key features of, summary, 96
Neuralgias
  defined, 95
  key features of, summary, 96
Neuritis, 95
Neuritis conversion to neuralgia
  clinical criteria for, 98
  diagnostic procedures, 98
  etiology of, 98
  treatment methods for, 98
Neuropathic pain, anticonvulsant drugs and recommendations for, 108
Neuroleptic medications, tardive dyskinesia and, 23
Neuroma, 95
  defined, 99
  key features of, summary, 96
Neurontin, 77, 104–105
Neuropathic conversion, steps in, 3
Neuropathic pain
  anticonvulsant drugs and recommendations for, 108
  antiepileptic drugs for, 35
  cancer-related, 213–214
    gabapentin and, 220
    ketamine and, 222
  capsicain for, 90
  carbamazepine and efficacy for, 101–102
  defined, 99
  methylprednisolone, prednisone and, 61
  nociceptive pain vs., 3, 95
  poor efficacy of opioids in, 77
  topical anesthetics for, 87
  tricyclic antidepressants for, effectiveness of, 132
Neuropathic pain conditions, key features of, summary, 96
Neuropathic pain diagnosis, topical anesthetic challenge test in, 154–156
Neuropathic pain disorders
  amitriptyline and efficacy for, 133
  antipsychotics and, 137
  anxiolytics and, 138
  gabapentin and efficacy for, 105
  lamotrigine and efficacy for, 103–104
  lidocaine and efficacy for, 107–108
  norepinephrine reuptake inhibitors and, 136
  oxcarbazepine and efficacy for, 102–103
  phenytoin and efficacy for, 103
  selective serotonin reuptake inhibitors and, 135
  serotonin and norepinephrine reuptake inhibitors for,
    134
  stimulants and, 139
  tricyclic antidepressants and efficacy for, 133
  valproic acid and efficacy for, 106–107
  zonisamide and efficacy for, 104
Neuropathies, 95
  key features of, summary, 96
Neurosensory threshold testing, burning mouth syndrome and, 233
Neurosurgical procedures, in orofacial region, 224
Neurotransmitter substance P, capsaicin and, 89
Neutropenia oral ulcers
  causation, 197
  clinical presentation, 197
New daily-persistent headache, 17, 257, 259
NINDS. See National Institute of Neurologic Disorders and Stroke
Nitrofurantoin
  neuritis/neuropathies and, 98
  medication-induced, 18
NMDA-blocking agents, topical, 90–91
NMDA receptor antagonists, for musculoskeletal pain, 286–287
NMDA receptors, opioid desensitization and hypersensitization of, 78
N-methyl-D-aspartate
  for cancer pain management, 220, 226
  intravenous, for diagnosis, 160
N-methyl-D-aspartate-blocking drug, for chronic orofacial pain, 41
NNH score. See Number needed to harm score
Nocebo response, placebo reaction vs., 84
Nocebo-responsive patient, 86
Nocebo-responsive patients, 84–85
Nocebo-responsive reaction, role of learning on, 85
Nociceptive pain, neuropathic pain vs., 3, 95
Noncancer orofacial pain, opioids for, conclusion, caveats, and recommendations regarding, 79
Nonmalignant ulcerative conditions of mouth clinical criteria for, 22
etiology of, 22
Nonopioid analgesics, 47, 48, 50–52
acacetaminophen, 47, 48, 50–51
cancer pain management and, 219
for chronic orofacial pain, 62
oral formulations and dosing protocol, 48
tramadol, 51–52
Nonreducing displaced disk, 317
Nonsensate flaps, sensate flaps vs., cancer patients and, 218
Nonsteroidal anti-inflammatory drugs, 33, 47, 53–59, 66, 85, 86
administration of, 54
cancer pain management and, 219
cardiotoxicity and, 59
celecoxib, 58
for chronic orofacial pain, 30, 62
efficacy of, 91
primary mechanism of action, 34
for DDNR, 349
diclofenac, 56
diflunisal, 53
etodolac, 59
ibuprofen, 54–55
ketoprofen, 55–56
lichen planus and, 21
mechanism of action, 53–54
meclomenamate sodium, 56
meloxicam, 58–59
for musculoskeletal pain, 284–285
for myofascial pain and fibromyalgia, 282
nabumetone, 57
naproxen and naproxen sodium, 55
opioids co-administered with, 77
oral formulations and dosing protocol, 48–49
for orofacial pain, 156–158
piroxicam, 56
preferential and selective cyclooxygenase-2 inhibitory medications, 57–58
preventative analgesia and, 61–62
salicylates, 52–53
for TMJ arthritis, 315
topical
  adverse reactions, 88
  as diagnostic test for inflammation, 157–158
  formulations and dosing, 88
  indications, 88
for traumatic focal or regional myalgia, 274
Norepinephrine, serotonin vs., as pain inhibitor, 129, 131
Norepinephrine reuptake inhibitors
for pain control: FDA approval, off-label use, dose, 130
for pain suppression, 135–136
description, mechanism of action, and primary indications, 135–136
fibromyalgia, 136
metabolism, side effects, and adverse drug reactions, 136
neuropathic pain disorders, 136
starting dose, 136
Nortriptyline
for burning mouth syndrome, 241
for chronic daily headache or chronic migraine, 260
for chronic orofacial pain, 38
for chronic trigeminal neuropathy, 305
Medline search: classification, orofacial pain, facial pain, pain, 31
for myofascial pain and fibromyalgia, 282
for pain control: FDA approval, off-label use, dose, 130
for pain suppression, starting dose for, 133
“N” position exercise, 280
for TMJ arthritis, 314, 315
NRIs. See Norepinephrine reuptake inhibitors
NSAIDs. See Nonsteroidal anti-inflammatory drugs
Nuclear factor, oral mucositis pathogenesis and, 186–187
Nucleoside antibiotics, antinociceptive action of, 147
Number needed to harm
chronic trigeminal neuropathy and, 304
tricyclic antidepressants and, 140
Number needed to treat
chronic trigeminal neuropathy and, 304
NSAIDs and, 157
SSRIs and, 140
Nutrition, for oral mucositis management, 187–188
Nutritional-deficiency, burning mouth syndrome and, 235
Nutritional-imbalance polyneuropathies, causes of, 18
Nutritional supplements, for TMJ arthritis, 315–316
Occipital nerve anesthetic, for cluster headaches, 265
Occipital nerve block
for headache, 166–167
for orofacial pain, 153–154
Occlusal appliances, 314–322
for bruxism, 332
Occlusal splints, 288
Octreotide, for cluster headaches, 265
Off-label medications, orofacial pain and, 42
Olanzapine, 140
for burning mouth syndrome, 242
oral tardive dyskinesia and, 23
for pain control: FDA approval, off-label use, dose, 130
tardive dyskinesia and dystonia and, 335
Older adults
opioids for cancer pain management in, 223
popularity of topical medications and, 86
psychopharmacologic agents and, 139
trigeminal neuralgia and, 96
OM. See Oral mucositis
OMAS. See Oral Mucositis Assessment Scale
OMD. See Oromandibular dystonia
ONB. See Occipital nerve block
Opana-ER, 72
Open condyle locking and open dislocation, clinical manifestations of, 344
Open dislocations, in temporomandibular joint, 12–13
Open MRI, internal derangement and, 346–347
Ophendrine, 116
Ophthalmoplegic migraine, 16, 251
Opioids, 30, 42
cancer pain management and, 76, 223
for chronic daily headaches, 17
for chronic orofacial pain, 32
chronic use of, for noncancer pain, 73–76
evidence suggested for, 74–75
quality of life and, 75–76
intravenous, for diagnostic-predictive purposes, 160
for musculoskeletal pain, 286
for pain, 9
dside effects of, 74
special considerations with, 78–79
alternate forms of opioid delivery, 78–79
endogenous-opioid-induced tolerance to exogenous opioids, 77
intravenous, intrathecal, or epidural delivery of, 79
preventing tolerance to, strategies for, 77–78
recognizing opioid-seeking behavior, 78
Opioids for chronic orofacial pain
nonmalignant chronic pain, 66–76
opioid side effects, 73
Schedule II opioids, 69–73
Schedule III opioids, 66–69
risk-versus-benefit analysis, 66
Orabase, 155
Orabase-B, 155
Oral cancer
pain as first clinical sign of, 213
trigeminal neuropathy and, 96
Oral dysesthesia, 232
Oral dyskinesia, 335–336
differential diagnosis of, 336
prevalence of, 335
treatment of, 335–336
Oral hygiene, for oral mucositis management, 187
Oral infection, clinical presentation, 236
Oral inflammatory disease, chronic, facial pain related to, 20–22
Oral motor disorders, facial pain related to, 22–24
Oral mucositis, 21, 184–185
   cellular and molecular events in model of pathogenesis for, 186
   clinical presentation with, 184
      chemotherapy-induced, 165
   consequences, 185–186
   epidemiology, 185
   etiology of, 185
   grading severity of, 184
   location, 184
management of, 187–191
   amifostine, 190–191
   basic oral hygiene, diet, and nutrition, 187–188
   benzydamine hydrochloride, 190
cryotherapy and, 189
   glutamine, 191
   granulocyte-macrophage colony stimulating factor, 190
   keratinocyte growth factors, 190
   low-level laser therapy, 191
   mucosal protective agents, 189
   pain control medications, 188–189
   prevention of secondary infections, 188
pathogenesis, 186
   cytokines and nuclear factor, 186–187
   radiation-induced, clinical presentation, 165
   recommendations on use of medications for, 203
   reducing severity of, 189–191
Oral Mucositis Assessment Scale, 184
Oral Mucositis Weekly Questionnaire-Head and Neck Cancer, 185
Oral parafunction, 24
   confirmatory or exclusionary diagnostic methods, 9t
Oral sponges, oral ulcerations and use of, 198
Oral squamous cell carcinoma, clinical features of, 192
   avoidance of causative and contact allergy agents, 198–199
   modified oral hygiene, 198
   topical antiseptic agents and antibacterial mouthrinses, 198
Oral pain
   anesthetic test protocol of USC Orofacial Pain and Oral Medicine Clinic, 155t
   botulinum toxin for orofacial pain disorders, 169–177
   cancer pain in the jaw and, 22
   chronic
description of, 29
differential diagnosis and etiology of, 3, 6
   efficacy of topical anesthetics for, 87–88
   commonly used topical medications for, 86–87
   comparative intravenous infusions for diagnostic/predictive purposes, 159–160
   intravenous NMDA for diagnosis of, 160
   lidocaine challenge test, 159–160
   morphine infusion challenge test, 160
corticosteroids and anti-inflammatory medications in, 156–158
   injectable steroids as diagnostic test for inflammation, 158
   topical NSAIDs as diagnostic test for inflammation, 157–158
diagnostic dilemmas in, 151–152
   accuracy of diagnostic tests, 151–152
effect of inactive substances in differential diagnosis of, 152
   source of pain not always visible on imaging studies, 151
   withdrawal of medications as diagnostic test, 152
diagram for anesthetic test, 156
   as first sign of oropharyngeal and nasopharyngeal cancer, 213
   limited opening testing, 158–159
   local anesthetic use in, 152–156
   needle-and injection-based interventional treatments, 164–169
pharmacotherapeutic management of: conclusions, 42–43
   prevalence of, 6
   recommendations on use of medications as diagnostic tests, 161
Index

389

special-case medications, 160–161
carbamazepine, 160–161
indomethacin, 161
visual analog scale for anesthetic test, 155
Orofacial pain (OFP) diseases, 29
most common, and distinguishing clinical features, 4–6
probable etiologies associated with most common, 7–8
Orofacial region, neurosurgical procedures in, 224
Oromandibular dyskinesia, recommendations for
diagnosis/management of, 338–339
Oromandibular dystonia, 327–335
anticholinergic therapy for, 334
botulinum toxin and, 334
management of, 333–334
with botulinum toxin, 334
miscellaneous drugs for movement disorder therapy,
334–335
prevalence of, 333
Oromandibular motor disorders and facial spasms,
botulinum toxin for, 171–172
Oropharyngeal cancer
orofacial pain as first sign of, 213
speech, masticatory, and swallowing deficits in,
215–217
Oropharyngeal cancer patients, types of pain reported as
initial symptom in, 213–214
Orphenadrine
D- and X-level interactions with, 125–126
description, mechanism of action, and primary
indications, 119
efficacy for musculoskeletal pain associated with spasm,
119
metabolism, side effects, and adverse drug reactions,
119
starting dose, 119
Orphenadrine citrate, for musculoskeletal pain, 158
Osteoarthritis
acetaminophen and, 50
celecoxib and, 58
description and prevalence, 312
doxycycline and progression of, 146
eye signs of articular cartilage loss in, 311–312
pain with, 321
polyjoint, TMJ affected by, 4–6
of TMJ, 13, 14, 314
triamadol for, 51
Osteoarthritis, 345
Osteophytes, 313
Osteoporosis, orofacial pain and, 6
Over-the-counter medications, for episodic headaches,
254–255
Oxaliplatin, signs/symptoms of peripheral neuropathy and,
214–215
Oxazepam, for pain control: FDA approval, off-label use,
dose, 131–132
Oxcarbazepine
for cancer pain management, 220
for chronic orofacial pain, 35–36
description, mechanism of action, and primary
indications, 102
Medline search: classification, orofacial pain, facial
pain, pain, 31
neuropathic pain disorders and efficacy of,
102–103
recommendations for neurogenic and neuropathic
pain, 108
side effects and adverse drug reactions, 102
starting dose, 102
trigeminal neuralgia and efficacy of, 102
Oxycodone, 76
adverse effects, 71
for cancer pain management and, 223
for chronic orofacial pain, 32
dosage for, 70
efficacy for acute pain, 71
efficacy for chronic pain, 71
indications for, 70
Medline search: classification, orofacial pain, facial
pain, pain, 31
opioid antagonist combined with, 79
Oxycontin, 70
Oxygen, for cluster headaches, 257, 257–258
Oxymorphone
for cancer pain management and, 223
dosage for, 72
efficacy for acute pain, 72
efficacy for chronic pain, 72
indications for, 72
Oxymorphone hydrochloride, 72
Pain
botulinum toxin and, 172–176
clinical criteria for, 95
as first clinical sign of oral cancer, 213
opioid therapy for, 9
osteoporosis, 321
prevalence in cancer patients, 212
visual analog scales of, 137
as “vital sign,” 129
Pain control, various psychopharmacologic medications
used in, 130–131
Painful polyneuropathies
Pain management
  choosing medication for, 70t
goal of, 76
Pain pressure threshold, 166
Palifermin, cytoprotective effect of, 190
Panoramic radiographs of TMJ, internal derangement and, 346t
Parafaccion
  habitual, and secondary hypertonicity, 24
clinical criteria for, 24
etiology of, 24
internal derangement and, 345, 345t
primary myalgia due to, 9
Parafaccion-induced myalgia, 275
Parafussions, 326
Paraneoplastic pemphigus
causation, 196
clinical presentation with, 196
Parents, prescription drug abuse among, 78
Parkinsonian reactions, extrapyramidal syndrome reaction and, 336
Parkinson’s disease, 326, 333
Paroxetine, 38, 68
  for burning mouth syndrome, 240
  extrapyramidal reactions and, 337
  motor side effects with, 24
  for pain control: FDA approval, off-label use, dose, 130t
  for pain suppression, 134
Paroxysmal hemicrania
characteristics and treatment for, 252
features of, 252t
Passive stretch test, for internal derangement, 346t, 347
Patient-controlled analgesia, 188
Paxil, 68
PCA. See Patient-controlled analgesia
Pectoralis flaps, cancer patients and, 218
Pemoline, extrapyramidal reactions and, 337, 339
Pemphigus, 35
Pemphigus vulgaris, 195
causation, 196
clinical criteria, 20–21
clinical features, 192t
clinical presentation, 195–196
confirmatory or exclusionary diagnostic methods, 9t
definitive diagnosis of, 196
distinguishing clinical features, 5t
etiology of, 8t, 21, 193t
orofacial pain due to, 20
Penicillin, dental pulpal infections and, 145
Pentoxifylline, for limited mouth opening in cancer patients, 215
Percocet, 70
Periodic leg movements
  antidepressants and, 336
  clonazepam for, 124
Periostat, 147
Peripheral cranial neuretomies, 224
Peripheral muscle nociceptor sensitization, masticatory muscle blood flow and, 276
Peripheral neuroma, 18
Peripheral neuropathy, chemotherapy-induced, 213
Peripheral sensitization, chronic trigeminal neuropathy and, 99, 299–300
PH. See Paroxysmal hemicrania
Phantom tooth pain, 19, 99, 178, 296
  final recommendations for, 306
  opioids used for, 74
  patient characteristics, 297
Pharmacologic treatment success, defining, 29
Pharmacophobic patient, motivational interviewing for, 84
PharmNet, 78
Pharyngeal cancer, trigeminal neuropathy and, 96
Phenol nerve block, for trigeminal neuralgia, 168–169
Phentermine, extrapyramidal reactions and, 337, 339
Phenytoin, 77, 108
  description, mechanism of action, and primary indications, 103
  neurologic pain disorders and efficacy of, 103
  side effects and adverse drug reactions, 103
  starting dose, 103
  trigeminal neuralgia and efficacy of, 103
PHN. See Postherpetic neuralgia
Phototherapy
  for autoimmune oral mucosal reaction
    adverse reactions, 202
    indication and dosing, 202
Pimecrolimus
  for autoimmune oral mucosal reaction
    adverse reactions, FDA black box warning, 201
    indications and dosing, 201
Piroxicam
  adverse effects, 56
  for chronic orofacial pain, 34
  dosage, 56
  efficacy for chronic pain, 56
  indications, 56
  Medline search: classification, orofacial pain, facial pain, pain, 31t
  oral formulations and dosing protocol, 49t
Placebo effect, of antibiotics, 147–148
Placebo reaction, nocebo response vs., 84
Platinum-derived compounds, chemotherapy-induced peripheral neuropathy and, 213
PLM. See Periodic leg movements
PLM index (PLMI), 336

Poliovirus
facial pain related to trigeminal neuritis and, 7t
viral-induced polyneuritis and, 18, 98

Polyarteritis nodosa, 249
Polyarthritic osteoarthritis, 13
Polyjoint arthritis, trigeminal sensory neuropathy and, 15
Polyjoint osteoarthritis
prevalence of, 319
secondary, defined, 14
TMJ and, 319–320
clinical criteria, 14
confirmatory or exclusionary diagnostic methods, 8t
etiology of, 7t, 14

Polymyalgia rheumatica, 249

Polyneuritis
causes of, 18
diabetic neuropathy and, 18

Polyneuritis involving the trigeminal nerve, 97–98
clinical criteria, 97–98
diagnostic procedures, 98
etiology of, 98
treatment methods for, 98

Polyneuropathy, duloxetine for, 140

Polysomnography, bruxism measured with, 330

Posterior disk displacement of TMJ disk, clinical criteria
for, 13

Postherpetic neuralgia, 42
capsaicin for, 90
clinical criteria for, 19
confirmatory or exclusionary diagnostic methods, 9t
etiology of, 19, 98
ibuprofen and, 55
key features of, summary, 96t
lidocaine patch for, 158
pregabalin for, 106
topical lidocaine for, 87, 88
treatment of, 98

Post-traumatic headache, 250

Posture, head and neck, masticatory myogenous pain and,
278

PPNs. See Painful polyneuropathies

PPT. See Pain pressure threshold

Prayer, cancer pain and, 226

Prednisolone, 201
Bell’s palsy and, 41
glucocorticoid potency and duration of action, 199t

Prednisone, 62
adverse effects, 60
chronic daily headaches and, 61
chronic musculoskeletal pain and, 60–61
chronic pain and efficacy of, 60
for cluster headaches, 265
dosage, 60
glucocorticoid potency and duration of action, 199t
indications for, 60
neuropathic pain, 61
oral formulations and dosing protocol, 49t
rheumatoid arthritis and, 60

Pregabalin, 42, 77, 105–106
for burning mouth syndrome, 241t
for cancer pain management, 220
for chronic orofacial pain, 36
for chronic trigeminal neuropathy, 305
description, mechanism of action, and primary
indications, 105–106
Medline search: classification, orofacial pain, facial
pain, pain, 31t
for musculoskeletal pain, 286, 289
neuromas and treatment with, 99
neuropathic pain disorders and efficacy of, 106
side effects and adverse drug reactions, 106
starting dose, 106

Prescription drugs, abuse of, 78
Pressure pain threshold, drugs for movement disorder
therapy and, 334, 335–335

Preventative analgesia, 61–62

Pridinol mesilate, 334, 335

Primary burning mouth syndrome, clinical presentation,
236t
Primary chronic daily headaches, defined, 257
Primary closure, speech and swallowing function in cancer
patients and, 217
Primary damage response phase, oral mucositis
pathogenesis, 186, 186

Primary dystonias, 333
Primary headaches, 253t
types of, 248
Primary myalgia, 9–10
clinical criteria for, 10
etiology of, 7t, 10
Primary myalgia due to stress and/or parafunction, criteria
for, 273t
Primary polyjoint osteoarthritis, 14, 319
Procaine, trigger-point injections and, 154

Prochlorperazine
for pain control: FDA approval, off-label use, dose,
130t
tardive dystonia/EPS and, 336

Prolotherapy, 177
for orofacial pain and spasm, 166
Promethazine, tardive dystonia/EPS and, 336
Pro-nociceptive sensitization, opioids and, 77
Propoxyphene, FDA black box warning, 66–68
Index

Propranolol
  for chronic daily headache or chronic migraine, 260
  for chronic orofacial pain, 37–38
  Medline search: classification, orofacial pain, facial pain, pain, 31
Proteoglycans, 311
Proteoglycans, osteoarthritis and loss of, 313
Proton pump inhibitors, NSAIDs and, 54
Protriptyline
  for pain control: FDA approval, off-label use, dose, 130
  for pain suppression, 133
Proximal interphalangeal (PIP) joint, 319
Prozac, 68
Psilocybin, for cluster headaches, 265
Psoriasis, 320
Psychopharmacologic agents for chronic pain, 129–140
  antidepressants and pain suppression, 131–137
  antipsychotics and pain, 137
  anxiolytics, 138
  introduction to, 129
  medication type, FDA approval, common off-label use, dosage, 130–131
  older adults and special concerns with, 139
  recommendations for, 139–140
  serotonin vs. norepinephrine as pain inhibitor, 129, 131
  stimulants and pain, 139
Psychostimulants, 129
PTH. See Post-traumatic headache
Pulpal toothache, trigeminal neuropathy vs., 19
Pulpitis, clenching-induced, 303–304
PV. See Pemphigus vulgaris
Qi, 164
Quality of life (QOL)
  chronic daily headache and, 266
  opioids and, 75–76
  oral mucositis and, 185
  rheumatoid arthritis and, 320
Quantitative theory tests, burning mouth syndrome and, 238
Quetiapine, for pain control: FDA approval, off-label use, dose, 130
RA. See Rheumatoid arthritis
Radial forearm flaps, innervated or noninnervated, cancer patients and, 218
Radiotherapy
  for cancer, orofacial symptoms and, 213
  oral mucositis and, 22, 184
  trismus and, 214
Randomized, blinded clinical trials, masticatory myogenous pain treatment and, 277
Randomized clinical trials, 30
Rapid-eye-movement (REM) sleep, sleep bruxism during, 330
RAS. See Recurrent aphthous stomatitis
Raynaud’s syndrome, 98
  KR5500 and, 147
  trigeminal sensory neuropathy and, 15
RBCTs. See Randomized, blinded clinical trials
RCTs. See Randomized clinical trials
Reactive oxygen species, oral mucositis and production of, 186
Rectal interventions, opioids and, 73
Rectus abdominus flaps, innervated or noninnervated, cancer patients and, 218
Recurrent aphthous disease, etiology of, 193
Recurrent aphthous stomatitis
  causation, 197
  clinical features of, 192
  clinical presentation with, 197
  herpetiform aphthae, 197
  major oral pahthae, 197
  minor oral aphthae, 197
  Reducing displaced disk, 317
  Referred pain phenomena, 273
Regional myalgia, 9
Reiter’s syndrome
  causation, 196
  clinical features of, 192
  clinical presentation with, 196
  etiology of, 193
Relafen, for orofacial pain, 157
Relaxation techniques, cancer pain and, 226
Relpax, for episodic migraines, 256
Renal failure polyneuropathy, 18
Repifermin, 190
Retinoids
  for autoimmune oral mucosal reaction
    adverse reactions, 202
    indications and dosing, 202
Retrodiscitis, 13
Review of systems, determining etiologies and, 277
RF. See Rheumatoid factor
Rheumatic arthritis
  TMJ and
    distinguishing clinical features, 4
    etiology of, 7
Rheumatic diseases, prevalence and costs of, 311–312
Rheumatoid arthritis, 30, 35, 313
  anti-inflammatory effect of minocycline in, 146
  celecoxib and, 58
  chronic, characteristics of, 15
  methylprednisolone, prednisone and, 60–61
Index

TMJ and, 14–15, 320, 320
clinical criteria and, 14–15
etiology of, 15
treatment goals in, 321
Rheumatoid factor, rheumatoid arthritis and, 15
Rhythmic masticatory muscle activity, sleep bruxism and, 330, 331
Risperal, oral tardive dyskinesia and, 23
Risperidone
oral tardive dyskinesia and, 23
for pain control: FDA approval, off-label use, dose, 130

tardive dystonia and dyskinesia and, 335
Ritalin, extrapyramidal reactions and, 339
Rizatriptan
for chronic orofacial pain, 36–37
for episodic migraines, 256
Medline search: classification, orofacial pain, facial pain, pain, 31
RMMA. See Rhythmic masticatory muscle activity
Rofecoxib, 34
ROS. See Review of systems
Rubefacients, topical, 88–89
Saforis, 191
SAHs. See Subarachnoid hemorrhage headaches
Salicylates, 52–53, 85
aspirin, 52–53
cardioprotective effect of, 61
for chronic orofacial pain, 62
diflunisal, 53
oral formulations and dosing protocol, 48

topical, 88
Saline, trigger-point injections for orofacial pain and spasm and, 165
Salivary biomarkers, burning mouth syndrome and, 237
Scalp tenderness, temporal arteritis and, 15
Schedule II opioids, 69–73
fentanyl, 71
hydromorphone, 71–72
methadone, 72–73
morphine, 69–70
oxycodone, 70–71
oxymorphone, 72
Schedule III opioids, 66–69
characteristics of, 66
codeine, 68–69
hydrocodone, 67–68
Schizoaffective psychoses, 85
Schizophrenia, 85
Scleroderma
sensory neuropathy and, 14
trigeminal sensory neuropathy and, 15
Secondary brain abscess, 250
Secondary burning mouth syndrome, clinical presentation, 236
Secondary dystonias, 333
Secondary headaches
diagnosis of, 248
IHS classification of, 249
Secondary infections, preventing, oral mucositis management and, 188
Secondary masticatory muscle spasm, botulinum toxin and, 171
Secondary myalgia, 7, 9
due to active local pathology, 10–11
clinical criteria, 10
etiology of, 10–11
Secondary polyjoint osteoarthritis, 14, 319
Sedative agents, for musculoskeletal pain, 287–288
Selective serotonin receptor inhibitors, for pain control:
FDA approval, off-label use, dose, 130
Selective serotonin reuptake inhibitors, 68
for cancer pain management, 220, 221
for chronic daily headaches, 264
for chronic orofacial pain, 38–39
for chronic trigeminal neuropathy, 305
for musculoskeletal pain, 284, 288
for myofascial pain and fibromyalgia, 282
NNT score for neuropathic pain, 140
for pain suppression
description, mechanism of action, and primary indications, 134
fibromyalgia, 135
metabolism, side effects, and adverse drug reactions, 134–135
neuropathic pain disorders, 135
starting dose, 134
tardive dystonia/EPS and, 336
Self-directed treatment, for masticatory myogenous pain, 277–278
Self-inducing drugs, 100
Sennoside, 73
Sensate flaps, nonsensate flaps vs., cancer patients and, 218
Serologic biomarkers, burning mouth syndrome and, 237
Serotonergic agents, extrapyramidal reactions and, 337
Serotonin, norepinephrine vs., as pain inhibitor, 129, 131
Serotonin and norepinephrine reuptake inhibitors, 76
for cancer pain management, 220, 221
for chronic pain, 139–140
for musculoskeletal pain, 284, 288
for myofascial pain and fibromyalgia, 282
for pain control: FDA approval, off-label use, dose, 130
pain suppression and
Serotonin and norepinephrine reuptake inhibitors (cont’d)
description, mechanism of action, and primary
indications, 134
fibromyalgia, 134
metabolism, side effects, and adverse drug reactions, 134
neuropathic pain disorders, 134
starting dose, 134
Serotonin-noradrenaline reuptake inhibitors, 38
Serotonin receptor modulators, 140
for pain control: FDA approval, off-label use, dose, 130
for pain suppression, 136
fibromyalgia, 136
metabolism, side effects, and adverse drug events, 136
neuropathic pain disorders, 136
starting dose, 136
Serotonin-related adverse drug events, 137
Serotonin syndrome, 124
Sertraline, 68
for burning mouth syndrome, 240
extrapyramidal reactions and, 337
for pain control: FDA approval, off-label use, dose, 130
for pain suppression, 134
SGB. See Stellate ganglion block
Shingles, 97
Short-lasting unilateral neuralgiform headaches, 41
Side effects
of clonazepam, 39
of gabapentin and pregabalin, 36
of NSAIDs, 34
of opioids, 73, 74
of oxcarbazepine, 35
of topiramate, 36
of tramadol, 51
Signal amplification phase, oral mucositis pathogenesis, 186, 186
Simple open locking, clinical criteria for, 13
Sinus infection, 97
6-methoxy-2-naphthylacetic acid (6-MNA), 57
Sjögren’s syndrome, trigeminal sensory neuropathy and,
7t, 14, 15, 98
SJS. See Stevens-Johnson syndrome
Skeletal muscle relaxants, 39. See also Muscle relaxants
antispasticity drugs vs., 116
cancer pain management and, 222–223
for orofacial pain, 158–159
prescribing, reasons for, 115
Sleep bruxism
defined, 330
pathophysiology of, 330–331
recommendations for management of, 338
Slow twitch type 1 fibers, ischemia and, 273
Small afferent fiber atrophy theory, burning mouth
syndrome and, 238
SMP. See Sympathetically maintained pain
SNOOP, dangerous (secondary) headaches and, 248
SNRIs. See Serotonin and norepinephrine reuptake
inhibitors
Sodium channel blockers, for chronic orofacial pain, 35
Sodium diclofenac
for chronic orofacial pain, 34
Medline search: classification, orofacial pain, facial
pain, pain, 31t
Sodium hyaluronate injections
intra-articular, for DDWR, 348
for TMJ arthritis, 317, 322
Somatostatin, for cluster headaches, 265
Sore mouth, 232
Sore tongue, 232
SPA. See Sphenopalatine ganglion block
Spasm, spasticity vs., 125
Spasmytics, 116
Spasticity
defined, 116
spasm vs., 125
Speech deficits, in head and neck cancer patients, 215–217
SPGB. See Sphenopalatine ganglion block
Sphenopalatal nerve block, for orofacial pain and spasm,
167
Sphenopalatine ganglion block, 167
for headaches, 256
for orofacial pain, 153
Spinal analgesics, cancer pain management and, 79
Spinal cord injury, long-term spasticity due to, 120
Spondyloarthropathies, 320
SSRIs. See Selective serotonin reuptake inhibitors
St. John’s Wort (Hypericum perforatum extract), for
burning mouth syndrome, 243
Stellate ganglion, 167
Stellate ganglion blocks, 177
for orofacial pain, 153, 167–168
Steroid rinses
adverse effects, 200
indications and dosing, 200
potency, 200
Stevens-Johnson syndrome, 194
carbamazepine and, 101
modafinil and, 139
Stiff-man syndrome, 24
Stimulant drugs, 140
extrapyramidal reactions and, 337, 339
opioids co-administered with, 77
for pain control: FDA approval, off-label use, dose, 131t
Stimulants and pain
  description, mechanism of action, and primary indications, 139
  metabolism, side effects, and adverse drug reactions, 139
  fibromyalgia, 139
  neuropathic pain disorder, 139
  starting dose, 139
Stomatodynia, 232
Stomatopyrosis, 20, 232
Stress, chronic facial and jaw pain and, 9
Stretch therapy
  for DDNR, 349–350
  for masticatory myogenous pain, 279–280
Stroke syndromes, headache in, 249
Subarachnoid hemorrhage headaches, 248–249
Subchondral cyst formation, 313
Sucralfate, 189, 203
Sulfazalazine, 320
Sulfonamides, lichen planus and, 21
Sumatriptan
  for chronic orofacial pain, 36–37
  for cluster headaches, 257
  as a diagnostic test for orofacial pain, 160
  for episodic migraines, 256
  Medline search: classification, orofacial pain, facial pain, pain, 31t
SUNCT, 38, 251
  botulinum toxin for, 177
  characteristics and treatment for, 252
  features of, 252t
Superior laryngeal neuralgia, 97
Suramin, chemotherapy-induced peripheral neuropathy and, 213
Surgical excision, for cancer, orofacial symptoms and, 213
Swallowing deficits, in head and neck cancer patients, 215–217
Sympathetically maintained pain, 300
Sympathetic nerve block, 167
Sympathomimetic agents, topical, 90
Symptom Check List 90 Revised Questionnaire (SCL-90R), 237, 275
Synovial fluids, temporomandibular joint and, 311
Synovitis, 13
Synvisic, 317
Systemic lupus erythematosus, 196
Tacrolimus
  for autoimmune oral mucosal reaction
  adverse reactions, 201
  indications and dosing, 201
TACs. See Trigeminal autonomic cephalalgias
Tardive dyskinesia, 23
  extrapyramidal syndrome vs., 339
  risk factors for, 335
Taste threshold changes, burning mouth syndrome and, 20, 234
Taut bands, palpating muscles for, 115
Taxanes, chemotherapy-induced peripheral neuropathy and, 213
TCAs. See Tricyclic antidepressants
Teens, prescription drug abuse among, 78
Teeth clenching. See Tooth clenching
Tegretol, as a diagnostic test for orofacial pain, 160–161
Temazepam, for pain control: FDA approval, off-label use, dose, 131t
Temovate, 200
Temporal arteritis (giant cell arteritis), 249
  clinical criteria for, 15
  confirmatory or exclusionary diagnostic methods, 8t
  distinguishing clinical features, 4t
  etiology of, 7t, 15
Temporalis muscle hypertrophy, botulinum toxin and, 171
Temporomandibular disorders, 30
  age profiling of, 311–312
  muscle relaxants for, 115
  opioids for, caveats and recommendations relative to, 79
Temporomandibular joint
  general considerations about, 311
  normal, 311
  open dislocations and locking problems seen in, 12–13
  clinical criteria for, 13
  etiology of, 13
  osteoarthritis of, 13, 14
  polyjoint osteoarthritis and, 4t, 14
  etiology of, 7t
  primary local and regional myalgia, 273
  recent literature on reducing pain in, 30
  rheumatic arthritis and
    distinguishing clinical features, 4t
    etiology of, 7t
  secondary local and regional myalgia, 273
  synovial fluids and, 311
Temporomandibular joint arthritis, 311–322, 314
  acute, secondary myalgia and, 11
  description and prevalence of, 312
  genetic-based diagnosis and treatment of, 321
  local
    confirmatory or exclusionary diagnostic methods, 8t
    etiology of, 7t
  neuropathic pain and, 321
  opioids used for, 74
  pathophysiology of osteoarthritis, 312–313
Temporomandibular joint arthritis (cont'd)
polyjoint inflammatory, pharmacologic treatment of,
  320–321
polyjoint osteoarthritis, 319–320
recommendations on medications for, 321–322
rheumatic arthritis, 320
signs and symptoms, 313
treatment of, 313–319, 314
  corticosteroid injections, 316
hyaluronic acid injections, 314, 316–317
joint lavage or arthrocentesis treatment, 318–319
nonpharmacologic, 314–315, 314
  NSAID treatment, 314
  , 315
nutritional supplements, 315–316
topical medications, 317–318

Temporomandibular joint injection, 159
Temporomandibular joint internal derangements, 343–352
chronic TMJ dysfunction and joint arthrosis, 351
description of, 343
diagnostic tests for, 346–347, 346
  images and radiographs, 346, 347
passive stretch test, 247, 346
disk displacement with reduction, 343–344
disk replacement with no reduction, 344
mechanism and etiology of, 344–346
  abnormal biomechanical loading, 345, 346
  arthritic disease, 345, 345
  hypermobility, 345–345, 345
  list of potential etiologies, 345
  macrotrauma, 345, 345
  parafunction, 345, 345
most efficacious interventions for DDWR and DDNR,
  351–352
open condyle locking and open dislocation, 344
recommendations on treatment of DDWR and DDNR,
  352
treatment of DDNR, 348–351
  anesthetic-assisted joint mobilization, 349–350
  anti-inflammatory, muscle relaxant, self-applied
  physical therapy, 349
arthrocentesis for, 350
arthroscopic treatment, 350–351
treatment of DDWR, 347–348
  avoidance therapy for, 347–348
  nighttime use of lateral motion restriction appliances,
  348
Temporomandibular pain and dysfunction, botulinum toxin
  and, 174–175
TEN. See Toxic epidermal necrolysis
Tension-type headaches, 16–17
  chronic, botulinum toxin and, 175–176
  clinical criteria for, 17
confirmatory or exclusionary diagnostic methods, 9t
distinguishing clinical features of, 5t
description, mechanism of action, and primary
episodic, 250
etiology of, 7t, 17, 253–254
  jaw muscle activity, 253
  myofascial pain, 253–254
  pathophysiological mechanism for, 254
prevalence of, 16
SSRIs and, 135
Tenuate, extrapyramidal reactions and, 339
Tetracycline
  lichen planus and, 21
  metallic dysgeusia and, 234
Tetracycline-class antibiotics, antinociceptive action of,
  146–147
Tetrahydrocannabinol, oral, cancer pain and, 224
Thalidomide, chemotherapy-induced peripheral neuropathy
  and, 213
Therabite, 214, 215
Therapeutic outcome, cognition and expectation of, 84
Thermal therapy, masticatory myogenous pain and,
  278–279
Thigh flaps, innervated or noninnervated, cancer patients
  and, 218
Third-molar removal, jaw muscle trismus after, 122
“Thunderclap headache,” 248
Thyroid alterations, burning mouth syndrome and, 235
Tiagabine, 77, 116
  for cancer pain management, 220
  for chronic orofacial pain, 40
D- and X-level interactions with, 125
description, mechanism of action, and primary
indications, 121
efficacy for musculoskeletal pain associated spasm, 121
Medline search: classification, orofacial pain, facial
  pain, pain, 31
metabolism, side effects, and adverse drug reactions,
  121
starting dose, 121
Timolol
  for chronic daily headache or chronic migraine, 260
  for chronic orofacial pain, 37–38
Medline search: classification, orofacial pain, facial
  pain, pain, 31
Tizanidine, 116
  for chronic daily headache or chronic migraine, 260
  for chronic orofacial pain, 36
D- and X-level interactions with, 125
description, mechanism of action, and primary
indications, 121
efficacy for musculoskeletal pain associated spasm,
  122
Medline search: classification, orofacial pain, facial pain, pain, 31
metabolism, side effects, and adverse drug reactions, 121–122
starting dose, 121
TMDs. See Temporomandibular disorders
TMJ. See Temporomandibular joint
TMJ condyles, tissue-engineered, 321
TMJ DDNR
confirmatory or exclusionary diagnostic methods, 8
distinguishing clinical features, 4
etiology of, 7
TMJ DDWR
confirmatory or exclusionary diagnostic methods, 8
distinguishing clinical features, 4
etiology of, 7
TN. See Trigeminal neuralgia
TNF blockers, for TMJ arthritis, 321
Tolerance, opioid, 77–78
Tolperisone hydrochloride, 334, 335
Tongue
bald or atrophic, 235
burning, 20
geographic, 225
Tongue-blade therapy, for limited mouth opening in cancer patients, 215, 216
Tongue hyperactivity, botulinum toxin and, 172
Tongue tissue biopsy, burning mouth syndrome and, 236
Tooth clenching, 24, 326, 327
avoidance of, for masticatory myogenous pain, 278
experimental, injected algesic agents and jaw pain, 329–330
habitual, 326–330
harmfulness of, 328–329
overview, 328
self-reported frequency of, 328
studies in the laboratory, 326–327
studies in the natural environment, 326–328
masticatory myofascial pain and, 10
pulpitis induced by, 303–304
secondary hypertonicity and, 24
TMJ arthritis and avoidance of, 315
Toothettes, oral ulcerations and use of, 198
Topamax, 107
Topical analgesics
adverse reactions with, 88
chronic orofacial pain and efficacy of, 88, 91
formulations and dosing for, 88
indications for, 88
for pain control in oral mucositis, 188–189
Topical anesthetic challenge test, in neuropathic pain diagnosis, 154–156
Topical anesthetics, 87–88
adverse reactions with, 87
chronic orofacial pain and efficacy of, 87–88, 91
formulations and dosing with, 87
indications for, 87
for pain control in oral mucositis, 188–189
Topical corticosteroid agents, gels, and ointments for noninfectious and non-neoplastic ulcers
adverse effects, 200
indications and dosing, 199–200
potency, 200
Topical creams, for TMJ arthritis, 317–318
Topical medications
advantages of, over orally delivered medications, 86
commonly used, for orofacial neuropathic pain, 86–87
for musculoskeletal pain, 288
Topical NMDA antagonists, chronic orofacial pain and efficacy of, 92
Topical NMDA-blocking agents, 90–91
adverse reactions, 91
chronic orofacial pain and efficacy of, 91
formulations and dosing, 90
indications for, 90
Topical pain medications
delivery systems for, in orofacial region, 91
description of and reasons for using, 85–91
for orofacial neuropathic pain, 86
topical analgesics, 88
topical anesthetics, 87–88
topical NMDA-blocking agents, 90–91
topical rubefacients, 88–89
topical sympathomimetic agents, 90
topical vanilloid compounds, 89–90
recommendations for chronic orofacial pain, 91–92
Topical rubefacients, 88–89
adverse reactions, 89
chronic orofacial pain and efficacy of, 89
formulations and dosing, 89
indications for, 88–89
Topical sympathomimetic agents
adverse reactions, 90
chronic orofacial pain and efficacy of, 90, 92
formulations and dosing, 90
indications for, 90
Topical vanilloid compounds, 89–90
adverse reactions, 89
chronic orofacial pain and efficacy of, 89–90, 92
formulations and dosing, 89
indications for, 89
Topiramate, 77
for cancer pain management, 220
for chronic daily headache or chronic migraine, 260, 262
Topiramate (cont’d)
for chronic orofacial pain, 36
description, mechanism of action, and primary indications, 107
Medline search: classification, orofacial pain, facial pain, 31
migraines, cluster headaches and, 107
side effects and adverse drug reactions, 107
starting dose, 107
for SUNCT, 252
therapeutic drug monitoring for, 108
Torticollis, 23, 336
Toxic epidermal necrolysis
carbamazepine and, 101
modafinil and, 139
Toxin-induced polyneuropathy, causes of, 18
Tramadol, 62
adverse effects, 51
for burning mouth syndrome, 242
chronic musculoskeletal pain and, 51–52
for chronic orofacial pain, 32–33
dosage, 51
efficacy for chronic pain, 51
for fibromyalgia, efficacy of, 289
indications for, 51
Medline search: classification, orofacial pain, facial pain, 31
for musculoskeletal pain, 285–286
for myofascial pain and fibromyalgia, 282
for neuropathic and other nonmalignant chronic pain disorders, 52
oral formulations and dosing protocol for, 48
osteoarthritis and, 51
Transdermal therapy, for TMJ arthritis, efficacy of, 317–318
Trauma, chronic trigeminal nerve pain and, 297
Trauma-induced oral ulcers
causation, 193
clinical features of, 192
clinical presentation with, 193
etiology of, 193
Trazodone
for burning mouth syndrome, 244
for pain control: FDA approval, off-label use, dose, 130
Triamcinolone, 200
for chronic orofacial pain, 34–35
glucocorticoid potency and duration of action, 199
Medline search: classification, orofacial pain, facial pain, 31
for noninfectious and non-neoplastic ulcers, potency, 200
for TMJ arthritis, 316
Triazolam, 39
Tricyclic antidepressants, 86
as adjuvant analgesic, 76
for cancer pain management, 220, 226
for chronic orofacial pain, 38
recommendations, 139–140
for musculoskeletal pain, 283–284, 288
for myofascial pain and fibromyalgia, 282
oral mucositis and, 188
for pain control: FDA approval, off-label use, dose, 130
for pain suppression
amitriptyline, 132–133
imipramine, doxepin, clomipramine, nortriptyline, protriptyline, desipramine, 133
as preventatives for chronic daily headache, 260–261
recommendations for neurogenous and neuropathic pain, 108
Trigeminal autonomic cephalalgias, 38, 251, 252
botulinum toxin for, 177
pathogenesis of, 254
trigger-point and other injections for, 255–256
Trigeminal mononeuritis
clinical criteria, 97
diagnostic procedures, 97
etiology of, 97
treatment methods for, 97
Trigeminal nerve, polyneuritis and involvement of, 98–99
Trigeminal nerve damage, orofacial neurogenous pain and, 17
Trigeminal neuralgia, 95–96
botulinum toxin for, 176–177
capsaicin for, 90
carbamazepine and efficacy for, 101
clinical criteria for, 18, 95–96
confirmatory or exclusionary diagnostic methods, 9
diagnostic procedures, 96
distinguishing clinical features with, 5
etiology of, 18, 96
facial pain related to, etiology of, 7
gabapentin and efficacy for, 105
key features of, summary, 96
lamotrigine and efficacy for, 103
oxcarbazepine and efficacy for, 102
phenol nerve block for, 168–169
phenytoin and efficacy of, 103
treatment methods for, 96
Trigeminal neuralgia pain, local anesthetic blocks for, 154
Trigeminal neuralgia therapy, anticonvulsants and, 35
Trigeminal neuritis, 97–99
cancer-induced trigeminal pain, 98–99
facial pain related to, 17–18
clinical criteria, 17–18
etiology of, 7
neuritis conversion to neuralgia and, 98
polyneuritis involving the trigeminal nerve, 97–98
trigeminal mononeuritis, 97

Trigeminal neuroma
clinical criteria, 18, 99
confirmatory or exclusionary diagnostic methods, 9t
diagnostic procedures, 99
distinguishing clinical features with, 5t
etiology of, 18, 99
facial pain related to, etiology of, 7t
treatment methods for, 99

Trigeminal neuropathic pain
BoNT/A injections and, recommendations, 178
opioids used for, 73–74

Trigeminal neuropathy, 99–100
chronic, facial pain related to, 18–19
clinical criteria, 19
etiology of, 7t, 19
clinical criteria for, 99
diagnostic procedures for, 100
etiology of, 99–100
pulpal toothache vs., 19
treatment methods for, 100

Trigeminal sensory neuropathy, 98
confirmatory or exclusionary diagnostic methods, 8t
distinguishing clinical features, 4t
idiopathic, 15–16

Trigger-point injections
with local anesthetics, 154
for orofacial pain and spasm, 165–166

Trihexyphenidyl hydrochloride, for dystonia, 334

Triptans, 85
antimigraine activity of, 256
for cluster headaches, 257
as a diagnostic test for orofacial pain, 160

Trismus, 158
cancer-related, 213
in head and neck cancer patients, 214–215
muscle relaxants for, 115
third-molar removal and, 122

Trismus-induced secondary myogenous pain, 274–275
TRPV1 receptor, upregulated, burning mouth syndrome and, 238–239

True open dislocation, clinical criteria for, 13

TSN. See Trigeminal sensory neuropathy

TTHs. See Tension-type headaches

TTX-R sodium channels
carbamazepine for neuropathic pain disorders and, 101
chronic inflammatory hyperalgesia and, 300
Tuberculosis, clinical features of, 192t
Tumor necrosis factor alpha, neuropathic pain and, 300

Ulceration phase, oral mucositis pathogenesis, 186, 186
Ulcerative disease of the mucosa
confirmatory or exclusionary diagnostic methods, 9t
distinguishing clinical features, 5t
Ulcers, characteristics of, 191
Upper motor neurons, spasticity and, 116

Vagal neuralgia, 97

Valdecoxib, 34

Valproate, Medline search: classification, orofacial pain, facial pain, pain, 31t

Valproic acid, 106–107
for chronic orofacial pain, 36
description, mechanism of action, and primary indications, 106
neuropathic pain disorders and efficacy of, 106–107
side effects and adverse drug reactions, 106
starting dose, 106

Valsalva-induced headaches, 161
Vanilloid compounds, topical, 89–90
Vanilloid receptor, 89
Vapocoolant sprays, 159

VAS. See Visual analog scale

Vascular disorders, facial pain and, 14–16

Venlafaxine, 42
for cancer pain management, 220
for chronic orofacial pain, 38
Medline search: classification, orofacial pain, facial pain, pain, 31t
for pain control: FDA approval, off-label use, dose, 130t
PLMs and, 336

Verapamil
for chronic daily headache or chronic migraine, 260t
for chronic orofacial pain, 37–38
for cluster headaches, 265
Medline search: classification, orofacial pain, facial pain, pain, 31t

Videofluoroscopic swallowing studies (VFSS), oropharyngeal cancer patients and, 217

Vigabatrin, therapeutic drug monitoring for, 108

Vinca alkaloids, chemotherapy-induced peripheral neuropathy and, 213

Vincristine
neuritis/neuropathies and, 18, 98
signs/symptoms of peripheral neuropathy and, 214t

Viral-induced polyneuritis, causes of, 18, 98

Viral infections, oral ulcerative disease and, clinical features, 192t

Vision loss, temporal arteritis and, 15
Visual analog scale, 67, 137
acupuncture for orofacial pain and rating on, 164–165
anesthetic challenge test in neuropathy diagnosis and, 302
for anesthetic test, 155
drugs for movement disorder therapy and, 334
Vitamin deficiencies
burning mouth syndrome and, 20
facial pain related to trigeminal neuritis and, 7t
nutritional-imbalance polyneuropathies and, 18
Voltaren, 88
VR. See Vanilloid receptor

Web Tryp, 78
WHO. See World Health Organization
Willow bark, salicin in, 52
Women
bruxism in, 24
burning mouth syndrome and, 20, 235
cluster headaches and, 16
dyskinesias and, 22
episodic tension-type headaches and, 250
fibromyalgia and, 11
giant cell arteritis and, 15
masticatory myofascial pain and, 10
migraines and, 16, 250
paroxysmal hemicrania in, 252
pemphigoid and, 21
tardive dyskinesia and, 23

World Health Organization
analgesic ladder, 33, 76–77
for cancer pain management, modifications to, 223
nonopioid analgesics recommendations, 47
oral mucositis scale, 185t

Xerostomia. See also Oral mucositis
burning mouth syndrome and, 20
clinical presentation, 236t

Zolmitriptan, for episodic migraines, 256
Zoloft, 68
Zomig
for cluster headaches, 257t
for episodic migraines, 256
Zongran, 104
Zonisamide
for cancer pain management, 220
for chronic orofacial pain, 35–36
description, mechanism of action, and primary indications, 104
Medline search: classification, orofacial pain, facial pain, pain, 31t
for neuropathic pain, 108
efficacy of, 104
side effects and adverse drug reactions, 104
starting dose, 104
trigeminal neuralgia and, 104
Zyprexa, oral tardive dyskinesia and, 23